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Definitions & Key Indicator Descriptions 
Acceptable storage conditions for medicines:  A wholesaler or outlet is considered to have 
acceptable storage conditions for medicines if it is in compliance with all the following three 
standards: (1) medicines are stored in a dry area; (2) medicines are protected from direct sunlight; 
and (3) medicines are not kept on the floor. 
Adult equivalent treatment dose (AETD):  The number of milligrams of an antimalarial treatment 
needed to treat a 60kg adult whereby all dosage types found (tablet, suspension, syrup, etc.) are 
converted regardless of their original presentation (whether for child or adult).  The number of 
mg/kg used to determine the dose is defined as what is recommended for a particular drug 
combination in the treatment guidelines for uncomplicated malaria in areas of low drug resistance 
issued by the WHO.  Where this does not exist, a product manufacturer’s treatment guidelines are 
consulted.  See Appendix 6.3 for additional details  
Antimalarial combination therapy:  The use of two or more classes of antimalarial drugs/molecules 
in the treatment of malaria that have independent modes of action. 
Antimalarial:  Any medicine recognized by the WHO for the treatment of malaria.  Medicines used 
solely for the prevention of malaria were excluded from analysis in this report. 
Artemisinin and its derivatives:  Artemisinin is a plant extract used in the treatment of malaria.  The 
most common derivatives of artemisinin used to treat malaria are artemether, artesunate, and 
dihydroartemisinin. 
Artemisinin monotherapy (AMT):  An antimalarial medicine that has a single active compound, 
where this active compound is artemisinin or one of its derivatives. 
Artemisinin-based Combination Therapy (ACT):  An antimalarial that combines artemisinin or one of 
its derivatives with an antimalarial or antimalarials of a different class.  See to combination therapy. 
Availability of any antimalarial or RDTs:  The proportion of wholesalers in which the specified 
antimalarial medicine or RDT was found on the day of the survey, based upon an audit conducted by 
the interviewer.  For indicators of availability, all wholesalers who were eligible to participate after 
screening (i.e. had any antimalarial or RDT in stock at present or at any point in the 3 months prior to 
interview) are included in the denominator. 
Booster sample:  A booster sample is an extra sample of units (or in this case outlets) of a type not 
adequately represented in the main survey, but which are of special interest.  In Nigeria, the second 
ACTwatch Outlet Survey included one additional sub-district (also referred to as locality or cluster, 
see below) selected per stratum, within which all public health facilities and registered pharmacies 
were censused (see below). 
Censused sub-district:  Sampled areas, (defined in the first ACTwatch Outlet Survey as aggregations 
of existing electoral enumeration areas encompassing 10,000-15,000 people, and defined in the 
second ACTwatch Outlet Survey as localities, see below), where field teams conducted a full census 
of all outlets with the potential to sell antimalarials as part of the first ACTwatch Outlet Survey.  
During the second ACTwatch Outlet Survey, a full census of outlets was not feasible in all localities 
due to large population sizes and a different census approach was followed:  For all localities, a full 
census of public health facilities, private health facilities, and registered pharmacies was conducted; 
for localities with fewer than 50,000 inhabitants, a full census of PPMVs, general retailers, 
community health workers, and hawkers was conducted; for localities with more than 50,000 
inhabitants, the census of PPMVs, general retailers, CHWs, and hawkers was restricted to 3 electoral 
enumeration areas within that locality that were also selected for the ACTwatch Household Survey. 
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Combination therapy:  The use of two or more classes of antimalarial drugs/molecules in the 
treatment of malaria that have independent modes of action. 
Credit to consumers:  A wholesaler is considered to provide credit to consumers based on the 
response of the wholesaler. 
Distribution chain:  The chain of businesses operating from the factory gate/port of entry down to 
the retail level.  Also sometimes referred to as downstream value chain.  In this report, the terms 
distribution chain and supply chain are used interchangeably.  More specifically, the ‘private 
commercial sector distribution chain’ refers to any type of public or private wholesaler who served 
private commercial outlets, as well as private commercial wholesalers who served public sector or 
NGO outlets so that any transactions between public, NGO and private commercial sectors are 
noted. 
First-line treatment:  The government recommended treatment for uncomplicated malaria.  
Nigeria’s first-line treatment for Plasmodium falciparum malaria is artemether-lumefantrine, 
20mg/120mg, with artesunate-amodiaquine (4mg/10mg/kg) as an alternative first-line treatment. 
Inter-quartile range (IQR):  A descriptive statistic that provides a measure of the spread of the 
middle 50% of observations.  The lower bound value of the range is defined by the 25th percentile 
observation and the upper bound value is defined by the 75th percentile observation. 
Mark-up:  The difference between the price at which a product is purchased, and that at which it is 
sold.  Sometimes also referred to as margin.  In this report, the terms mark-up and margin are used 
interchangeably.  May be expressed in absolute or percent terms.  Because it is common for 
wholesalers to vary their prices with the volumes they sell, minimum, mid and maximum mark-ups 
were calculated in this report using price data collected from interviewees.  Key findings on price 
mark-ups at the wholesale level are reported using mid mark-up data.  As maximum and minimum 
selling prices were not collected at the retail level, only one set of absolute and percent retail mark-
ups is calculated. 
Absolute mark-up:  The absolute mark-up is calculated as the difference between the selling 
price and the purchase price per full-course adult equivalent treatment dose.  In this report, 
absolute mark-ups are reported in US dollars.  The average exchange rate during the data 
collection period for wholesale purchase prices (18 July to 8 September 2009) was 154.892 
Nigeria Naira (NGN) to US$1; the average exchange rate during the data collection period for 
retail purchase prices (4 August to 16 September 2009) was 155.566 Nigeria Naira (NGN) to 
US$1 (www.oanda.com).   
Percent mark-up:  The percentage mark-up is calculated as the difference between the 
selling price and the purchase price, divided by the purchase price. 
Maximum mark-up:  For wholesale level only, the absolute and percent maximum mark-ups 
are calculated as above using the difference between maximum wholesale selling price and 
the wholesale purchase price. 
Minimum mark-up:  For wholesale level only, the absolute and percent minimum mark-ups 
are calculated as above using the difference between minimum wholesale selling price and 
the wholesale purchase price. 
Mid mark-up:  For wholesale level only, the absolute and percent mid mark-ups are 
calculated as above using the difference between the average wholesale selling price (i.e. 
the mid-point between the maximum and minimum wholesale selling price) and wholesale 
purchase price.  
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Median:  A descriptive statistic given by the middle (or 50th percentile) value of an ordered set of 
values (or the average of the middle two in a set with an even number of values), which is an 
appropriate measure of central tendency of a skewed distribution of continuous data. 
Monotherapy:  An antimalarial medicine that has a single mode of action.  This may be a medicine 
with a single active compound or a synergistic combination of two compounds with related 
mechanisms of action.  
Non-artemisinin therapy (nAT):  An antimalarial treatment that does not contain artemisinin or any 
of its derivatives. 
Non-WHO prequalified ACTs:  ACTs that do not meet acceptable standards of quality, safety and 
efficacy as assessed by the WHO Prequalification of Medicines Programme, or have yet to be 
assessed as such.  (See WHO prequalified ACTs below)  
Oral artemisinin monotherapy:  Artemisinin or one of its derivatives in a dosage form with an oral 
route of administration.  These include tablets, granules, suspensions, and syrups and exclude 
suppositories and injections.   
Outlet:  Any point of sale or provision of a commodity to an individual.  Outlets are not restricted to 
stationary points of sale and may include mobile units or individuals.  Refer to Appendix 6.2 for a 
description of the outlet types visited as part of the ACTwatch Outlet Survey.   
Purchase price:  The price paid by businesses (i.e. wholesalers or outlets) for their most recent 
purchase of an antimalarial product from their suppliers.  This is different from selling price (see 
below).  Prices are reported in terms of full adult equivalent treatment dose treatment.  Prices are 
shown in US dollars.  The average exchange rate during the data collection period for wholesale 
purchase prices (18 July to 8 September 2009) was 154.892 Nigeria Naira (NGN) to US$1; the 
average exchange rate during the data collection period for retail purchase prices (4 August to 16 
September 2009) was 155.566 Nigeria Naira (NGN) to US$1 (www.oanda.com).   
Rapid-Diagnostic Test (RDT) for malaria:  A test used to confirm the presence of malaria parasites in 
a patient’s bloodstream. 
Screening/Eligibility criteria:  The set of requirements that must be satisfied before the full 
questionnaire is administered. In the ACTwatch Supply Chain Survey, a wholesaler met the screening 
criteria if (1) they had any antimalarial or RDTs in stock at the time of the survey visit, or (2) they 
report having stocked either antimalarials or RDTs in the past three months. 
Selling price:  The price paid by customers to purchase antimalarials.  For outlets, these customers 
are patients or caretakers; for wholesalers, these customers are other businesses or health facilities.  
Because it is common for wholesalers to vary their selling prices depending on the volumes 
purchased by the customer, data on maximum and minimum selling price charged for one unit by 
wholesalers were collected for each antimalarial product type in stock at the time of interview.   
Stock outs of ACT:  Reported in the affirmative as the percentage of interviewed wholesalers who 
reported to have always had at least one ACT in stock over the past 3 months.  All eligible (see 
Screening criteria above) wholesalers who were successfully interviewed were included in the 
denominator. 
Sub-district (SD):  The primary sampling unit, (also referred to as cluster or locality in the second 
ACTwatch Outlet Survey).  For the first ACTwatch Outlet Survey in Nigeria, these were created by 
aggregating existing electoral enumeration areas such that the aggregated population is 
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approximately 10,000 to 15,000 inhabitants.  However during the second ACTwatch Outlet Survey, 
sub-districts were defined as localities (i.e. existing local government administrative areas).  
Top selling antimalarial:  The antimalarial with the largest volume of adult equivalent treatment 
doses sold or distributed in the past week as reported by individual wholesalers.   
Treatment/dosing regimen:  The posology or timing and number of doses of an antimalarial used to 
treat malaria. This schedule often varies by patient weight. 
Volumes:  Volumes of antimalarials sold in the previous week are reported in terms of full-course 
adult equivalent treatment doses (or AETDs; see above for description). 
WHO prequalified ACTs:  ACTs that meet acceptable standards of quality, safety and efficacy as 
assessed by the WHO Prequalification of Medicines Programme.  This is a service provided by WHO 
to guide bulk medicine purchasing of international procurement agencies and countries for 
distribution in resource limited settings, often using funds for development aid (e.g. Global Fund 
grants).  More details on the list of prequalified medicines and the prequalification process may be 
found on the WHO website at: http://www.who.int/mediacentre/factsheets/fs278/en/index.html.  
Wholesalers:  Businesses that supply other businesses, which may include retailers or other 
wholesalers.  In this report, wholesalers are classified further into more specific categories defined 
by the type of businesses that they supply.  As some wholesalers will supply different types of 
businesses (e.g. both retail outlets and other wholesalers), these categories are not mutually 
exclusive and such wholesalers may appear in multiple categories.  These are defined below. 
Terminal wholesalers:  Wholesalers that supply retail outlets directly.  For example, 
wholesaler X is a terminal wholesaler if it supplies antimalarials to pharmacies and drug 
shops from which patients buy medicines.  Terminal wholesalers may supply retail outlets 
only, but may also supply other wholesalers. 
Intermediate-1 wholesalers:  Wholesalers that supply terminal wholesalers directly.  
Intermediate-1 wholesalers may supply terminal wholesalers only, but may also supply other 
types of wholesalers (such as other intermediate-1 wholesalers) and retail outlets. 
Intermediate-2 wholesalers:  Wholesalers that supply Intermediate-1 wholesalers directly.  
Intermediate-2 wholesalers may supply Intermediate-1 wholesalers only, but may also 
supply other types of wholesalers (such as terminal wholesalers) and retail outlets.  
Intermediate-3 wholesalers:  Wholesalers that supply Intermediate-2 wholesalers directly.  
Intermediate-3 wholesalers may supply Intermediate-2 wholesalers only, but may also 
supply other wholesalers (such as intermediate-1 or terminal wholesalers) and retail outlets.  
Wholesalers supplying retailers:  This is an analytical category specific to ACTwatch that 
groups together all wholesalers that may be categorised as a terminal wholesaler. 
Wholesalers supplying wholesalers:  This is an analytical category specific to ACTwatch that 
groups together all wholesalers that may be categorised as operating at an intermediate 
level of the supply chain (e.g. in this report, intermediate-1, intermediate-2 and 
intermediate-3 wholesalers).
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Abbreviations 
ACT artemisinin-based combination therapy 
AETD adult equivalent treatment dose 
AL artemether lumefantrine  
AMFm Affordable Medicine Facility - malaria 
AMT artemisinin monotherapy 
ASAQ aretesunate-amodiaquine 
ASMQ artesunate and mefloquine 
CMS Central Medical Stores 
CQ chloroquine 
DHA dihydroartemisinin 
DHA+PP dihydroartemisinin and piperaquine 
FMOH Federal Ministry of Health, Nigeria 
INT intermediate level (wholesaler of supply chain) 
IPT intermittent preventive treatment of malaria 
IQR inter-quartile range  
IRS indoor residual spraying 
ITN insecticide treated net 
LSHTM London School of Hygiene & Tropical Medicine  
MEC mutually-exclusive category of wholesalers 
MQ mefloquine 
NAFDAC National Agency for Food and Drug Administration and Control 
nAT non-artemisinin therapy 
NGN Nigerian Naira 
NGO non-governmental organisation 
NMCP National Malaria Control Programme 
OS ACTwatch Outlet Survey 
OTC over the counter 
PCN Pharmacists Council of Nigeria 
Pf Plasmodium falciparum  
PMG-MAN Pharmaceutical Manufacturers Group of the Manufac. Assoc. of Nigeria 
POM prescription only medicine 
PPS probability proportional to size 
PPMV Proprietary Patent Medicine Vendor 
PSI Population Services International  
RDT rapid diagnostic test 
RMM role-model mothers 
SFH Society for Family Health, Nigeria 
SP sulphadoxine pyrimethamine 
VAT value added tax 
WHO World Health Organization  
WS wholesaler 
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Executive Summary 
Background 
In Nigeria, as in many low-income countries, private commercial providers play an important role in 
the treatment of malaria.  To design effective interventions for improved access to accurate 
diagnosis and effective malaria treatment, there is a need to understand retailer behaviour and 
identify the factors that influence their stocking and pricing decisions.  Private commercial retailers 
are the last link in a chain of manufacturers, importers and wholesalers and their supply sources are 
likely to have an important influence on the price and quality of malaria treatment that consumers 
can access.  However, there is limited rigorous evidence on the structure and operation of the 
distribution chain for antimalarial drugs that serves the retail sector. 
 
The ACTwatch Supply Chain Study, one of the ACTwatch project components, aims to address this 
gap by conducting quantitative and qualitative studies on distribution chains for antimalarials in the 
ACTwatch countries (Nigeria, Cambodia, Benin, the Democratic Republic of Congo, Madagascar, 
Uganda and Zambia).  Other elements of ACTwatch include Retail Outlet and Household Surveys led 
by Population Services International (PSI).  This report presents the results of a cross-sectional 
survey of antimalarial drug wholesalers conducted in Nigeria between July and September 2009. 
 
Methods 
The Supply Chain survey was implemented by the London School of Hygiene & Tropical Medicine 
(LSHTM), with support from the Society for Family Health (SFH), Nigeria, conducted concurrently 
with the second round of the ACTwatch Outlet Survey implemented by SFH and PSI in 2009.  
Wholesalers operating at different levels of the supply chain that served a representative sample of 
four geographically defined zones in Nigeria (i.e. Lower North, South East, Upper North, South West) 
were sampled through a bottom-up approach during which wholesalers were identified by their 
customers until the top of the chain was reached.  For this purpose, 20 of the 76 sub-districts 
included in the first round of the ACTwatch Outlet Survey were used to form the sample for the 
ACTwatch Supply Chain Survey.  The sampling procedure used the list of the two top antimalarial 
wholesale sources (termed the terminal wholesalers) reported by each antimalarial retail outlet that 
participated in the 20 selected Outlet Survey sub-districts.  From these data a list of all terminal 
wholesalers mentioned was created.  All these terminal wholesalers were visited and invited to 
participate in the Supply Chain survey.  Wholesalers were eligible to participate if they met the 
following screening criteria: they had either an antimalarial or rapid diagnostic test (RDT) in stock at 
the time of interview, or they reported to have stocked either antimalarials or RDTs in the three 
months prior to interview.  During the interview, eligible wholesalers were also asked about their 
two top supply sources for antimalarials (termed the intermediate-1 wholesalers).  From these data, 
we created a list of all intermediate-1 wholesalers mentioned.  All these intermediate-1 wholesalers 
were visited and invited to participate in the Supply Chain survey, during which, as at previous levels, 
they were asked about their two top supply sources for antimalarials (termed the intermediate-2 
wholesalers).  This process was repeated until the factory gate or port of entry was reached. 
 
The supply chain survey collected data on the structure of the private commercial sector supply 
chain; wholesaler characteristics and business practices; wholesale outlet licensing and inspection; 
wholesaler knowledge, qualifications and training; and wholesale availability, purchase prices and 
mark-ups for antimalarials and RDTs.  Retail outlets’ purchase prices and mark-ups for antimalarials 
collected during the Outlet Survey in 2009 are also presented in this report as they form the last step 
of the supply chain before antimalarials reached patients/care takers and are therefore relevant to 
the study of the distribution chain. 
 
2 
Results 
 
STRUCTURE OF THE SUPPLY CHAIN: A total of 205 antimalarial wholesalers were identified, and 140 interviews 
were conducted. Each red dot on Figure 1 represents a mutually exclusive group of wholesalers and the array 
of arrows emanating from them describes the specific supply chain levels that each wholesaler group serves.  
Their percentage share is attached to each group. Figure 2 illustrates how the overlapping analytical categories 
used throughout this report are derived from the different mutually exclusive wholesaler categories depicted 
in Figure 1. The maximum number of steps from manufacturers’ factory gate to retail outlets was 5 with 
wholesalers operating across 4 overlapping levels: intermediate-3 (INT 3 WS), intermediate-2 (INT 2 WS), 
intermediate-1 (INT 1 WS) and terminal (TERMINAL WS) levels.  However, most antimalarials were likely to go 
through 3 steps (i.e. manufacturer  any intermediate wholesaler  terminal wholesaler  retailer), as most 
wholesalers either sold antimalarials only to retailers (60%) or only to other wholesalers (37%), and only 4% 
sold to both groups (Figure 2).  Wholesalers located in markets were an important source of antimalarials: 55% 
of all suppliers mentioned by retailers and 13% of all suppliers mentioned by wholesalers were located in large 
commercial markets in Lagos, Onitsha, Kano, Ibadan and Bauchi.  More than half of all wholesalers (56%) 
purchased antimalarials directly from manufacturers as one of their two top suppliers, some of whom arranged 
their orders through a sales representative from the manufacturer.  As a result, the supply chain is shaped as a 
pyramid with a broad base. The dashed line in Figure 1 from manufacturer to retailer indicates that a few 
retailers purchased antimalarials directly from manufacturers, although this was rare (2% of all suppliers 
mentioned by retailers were local drug manufacturers). 
 
Figure 1: Representation of the antimalarial 
distribution chain showing interactions between 
supply chain levels by mutually exclusive wholesaler 
category 
 
Note:  WS: wholesaler;  INT: intermediate 
Figure 2: Representation of the antimalarial 
distribution chain showing the overlap between 
wholesaler categories used for analysis 
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WHOLESALER CHARACTERISTICS:  Wholesalers had been in operation for a median of 8 years; however, this 
varied considerably.  Wholesale businesses supplying retailers were slightly smaller (median of 5 workers) than 
those supplying other wholesalers (median of 8.5 workers).  Nearly all wholesalers (97%) were observed to 
store their antimalarials appropriately (off the floor, in dry areas and out of direct sunlight); however, fewer 
wholesalers reported having been visited by a pharmaceutical inspector in the past year (71%), or reported 
employing a member of staff with a health qualification (63%).  In addition, only 9% of wholesalers were 
observed to have an up-to-date license (wholesale or retail) from the Pharmacists Council of Nigeria (PCN). 
More than three-quarters of all wholesalers interviewed had provided credit facilities to their customers in the 
past 3 months, but only a third (33%) reported delivering antimalarial orders.  
 
AVAILABILITY OF ANTIMALARIALS & RDTS:  Nearly all wholesalers (99%) had at least one antimalarial in stock 
at the time of interview, 86% had ACT in stock, and 83% stocked either artemether+lumefantrine (AL) or 
artesunate+amodiaquine (ASAQ), the recommended first line ACT treatments for uncomplicated Pf malaria in 
Nigeria.  Availability of other antimalarial drugs was comparable to that of ACT, with oral artemisinin 
monotherapies (AMT) being stocked by 73% of all wholesalers, and non-artemisinin therapies (nAT) by 88% of 
wholesalers. Only 4% of wholesalers stocked RDTs. 
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ANTIMALARIAL & RDT SALES VOLUMES:  The median number of adult equivalent treatment doses (AETDs) of 
antimalarials sold the week preceding the survey was 137.9 for ACT, 42.0 for any AMT, and 562.9 for nATs. 
AMTs were predominantly sold in tablet form: the median sales volume for AMT tablets was 28.1 AETDs vs. 1.0 
for oral liquid vs. 0.0 for injectable AMTs. The median sales volumes during the week preceding the survey for 
non-WHO prequalified ACTs (94.0 AETDs) was much higher than the volumes for WHO prequalified ACTs (4.8 
AETDs).  Among wholesalers who stocked antimalarials at the time of interview (n=135), for 45% the nAT 
sulphadoxine-pyrimethamine (SP) was their top selling antimalarial, followed by chloroquine (19%).  The next 
most common top selling antimalarials were the government recommended first-line treatments: AL for 13% 
and ASAQ for 6%.  Very few wholesalers sold RDTs during the week preceding the survey, and the median 
number of RDTs sold was 0. 
 
WHOLESALE PURCHASE PRICES:  The median wholesale purchase price (i.e. the price paid by wholesalers to 
purchase stock from their suppliers) per AETD varied across antimalarial drug categories.  Overall, AMTs had 
the highest median purchase price per AETD (US$ 4.13), followed by ACTs (US$ 3.55); while nATs had a much 
lower median purchase price of US$ 0.53. Tablets comprised a high proportion of all observed products in each 
drug category; and considering tablet dosage forms only, wholesalers purchased ACTs at a median price of US$ 
3.10 per AETD, US$ 2.07 for AMT, and US$ 0.35 for nATs.  The median wholesale purchase price for the 
government recommended first-line treatments, AL (US$ 4.13) and ASAQ (US$ 2.91), were at least 10 times the 
wholesale purchase price of SP (US$ 0.29).  The wholesale purchase price for RDTs was US$ 0.71 per test. 
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WHOLESALE MARK-UPS FOR ANTIMALARIALS & RDTS:  The median mid percent mark-ups were lowest on 
ACTs (18%), slightly higher on AMTs (20%), and highest on nATs (25%), but within each of these antimalarial 
categories, mark-ups were consistent across dosage forms. In absolute terms, mark-ups per AETD were the 
highest on AMT (US$ 0.87), followed by ACT (US$ 0.65) and nAT (US$ 0.16), corresponding to the differences in 
purchase prices across drug categories.  Wholesale percent mark-ups tended to be similar at different levels of 
the supply chain; however wholesalers supplying other wholesalers tended to apply higher percent mark-ups 
on non-tablet dosage forms (i.e. oral liquids and injectables) and on AMTs than wholesalers supplying retailers.  
For example, the median mid percent mark-up applied to AMTs by wholesalers supplying wholesalers was 
26.7% (corresponding to a median mid absolute mark-up of US$ 1.03); while wholesalers supplying retailers 
applied a median mid percent mark-up of 19.0% (corresponding to a median mid absolute mark-up of US$ 
0.83).  Although the median mid percent mark-ups for AL and ASAQ were similar to that for SP (AL: 15% vs. 
ASAQ: 20% vs. SP: 22%), there were considerable differences between median mid absolute mark-ups due to 
differences in purchase prices (AL: US$ 0.71 vs. ASAQ: US$ 0.65 vs. SP: US$ 0.07).  For RDTs, the median 
wholesale percent mark-up was 40%, equivalent to US$ 0.32 in absolute terms. 
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RETAIL PURCHASE PRICES:  Similar to the wholesale level, median retail purchase prices (i.e. the price paid by retailers to purchase stock from their suppliers) 
per AETD varied across antimalarial drug categories.  In private health facilities, Proprietary Patent Medicine Vendors (PPMVs)/drug stores, and “other” 
private outlets (supermarkets, kiosks, itinerant medicine sellers, etc.) ACTs were observed to have the highest median retail purchase prices per AETD 
(ranging from US$ 2.70 at private health facilities to US$ 3.21 at “other” private outlets), while nATs had the lowest median retail purchase prices per AETD 
(ranging from US$ 0.55 at “other” private outlets, to US$ 0.96 at private health facilities).  Pharmacies were observed to pay higher prices for ACTs and AMTs 
than other outlet types, as pharmacies tended to stock relatively more expensive dosage forms (i.e. oral liquids and injectables rather than tablets) than 
PPMVs/drug stores and “other” private outlets, and also stocked the highest proportion of antimalarials imported from Western countries. 
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RETAIL MARK-UPS FOR ANTIMALARIALS:  Median mid percent mark-ups among retailers tended to be higher compared to those observed among 
wholesalers.  For ACTs, the median mark-up varied across retailer category from 22% at PPMVs/drug stores to 42% at private health facilities; for AMT, 
median mark-up ranged between 22% at “other” private outlets (supermarkets, kiosks, itinerant medicine sellers, etc.), and 40% at private health facilities; 
and for nAT, between 27% at “other” private outlets, and 43% at private health facilities.  Mark-ups were relatively low and were infrequently observed to 
exceed 100%.  Variation in absolute mark-ups was also observed across antimalarial and retailer categories, corresponding closely with variations in purchase 
price: mark-ups on ACTs ranged between US$ 0.64 and US$ 0.96 across outlet categories; on AMT between US$ 0.62 and US$ 2.57; and on nAT between US$ 
0.16 and US$ 0.30. Although median percent mark-ups on ASAQ (25%-67%) were higher than on AL (13%-20%), the considerable difference in purchase 
prices meant that observed median absolute mark-ups on AL (US$ 0.64-US$ 1.11) were higher than on ASAQ (US$ 0.45-US$ 0.77). The median mid absolute 
mark-up for SP, on the other hand, ranged between US$ 0.13 at “other” private outlets and US$ 0.19 at private health facilities.  
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Conclusions 
This report has presented a number of important new insights into the market for antimalarial drugs in 
Nigeria.  The distribution chain had wholesalers operating on a number of levels giving an overall pyramidal 
shape.  However, most wholesalers either supplied only other wholesalers or only retailers, and many 
wholesalers were supplied by manufacturers, either directly or through a network of regional depots owned 
by the manufacturer or by a logistics company.  This means that most antimalarials are likely to go through 
either 2 or 3 steps from manufacturer to retailer.  Most wholesalers were not observed to have an up-to-
date license permitting the wholesale of antimalarials, and a number of those engaged in antimalarial 
wholesaling were only permitted to retail over-the-counter medicines.  Large markets were an important 
source of antimalarial purchasing, particularly for retailers.  Regardless of wholesaler type and location, 
ACTs, and in particular the first-line drugs AL and ASAQ, were observed to be available in most wholesalers.  
However, AMTs and nATs were also available at comparable levels, and in terms of sales volumes, those of 
nATs far exceeded sales volumes of ACTs.  At wholesale and retail levels, percent mark-ups on antimalarials 
were observed to be relatively low and consistent across antimalarial category and business type.  This may 
be due to a high degree of competition among wholesalers and retailers.  RDTs were not widely available at 
wholesale level; however, their wholesale purchase prices were low compared to ACT purchase prices.  
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1. Introduction & Objectives 
In Nigeria, as in many low-income countries, private commercial providers play an important role in the 
treatment of malaria.  To design effective interventions for improved access to accurate diagnosis and 
effective malaria treatment, there is a need to understand retailers' behaviour and identify the factors that 
influence their stocking and pricing decisions.  Private commercial retailers are the last link in a chain of 
manufacturers, importers and wholesalers, and their supply sources are likely to have an important 
influence on the price and quality of malaria treatment that consumers can access.  However, there is 
limited rigorous evidence on the structure and operation of the distribution chain for antimalarial drugs that 
serves the retail sector. 
 
This study aims to address this gap and constitutes an integral part of the ACTwatch project, a multi-country 
programme of research being conducted in Nigeria, Benin, Cambodia, the Democratic Republic of Congo 
Madagascar, Uganda and Zambia.  The overall goal of ACTwatch is to generate and disseminate evidence to 
policy makers on artemisinin-based combination therapy (ACT) availability and price in order to inform the 
development of policies designed to increase rates of access to effective malaria treatment.  Along with the 
Supply Chain Study, the ACTwatch project also includes Outlet and Household Surveys led by PSI and the 
Society for Family Health (SFH) in Nigeria. 
 
The objective of the Supply Chain component of ACTwatch is to document and analyse the supply chain for 
antimalarials and rapid diagnostic tests (RDTs) for malaria using quantitative (structured survey) and 
qualitative (in-depth interviews) methods for studying providers operating at each level of the chain.  This 
report presents the results of the structured survey of antimalarial drug wholesalers conducted in Nigeria 
between July and September 2009.  In order to provide a complete description of the supply chain for 
antimalarial drugs, the report also presents retail-level data on antimalarial purchase prices and mark-ups 
that were collected during the second round of the ACTwatch Outlet Survey by SFH Nigeria between August 
and September 2009. 
2. Country Background  
Economic Profile 
Nigeria is Africa’s most populous country and the eighth largest in the world with an estimated population of 
155.2 million. [1]  Located in West Africa, it is bordered by Niger in the north, Benin to the west, and 
Cameroon and Chad in the west, it is made up of six geopolitical zones, 36 states (plus the Federal Capital 
Territory of Abuja), and 774 Local Government Authorities (LGAs).  State governments have substantial 
autonomy and exercise considerable authority over the allocation and utilization of their resources, limiting 
the influence of the federal government over state and local government affairs. [2]  Since gaining 
independence from Britain in 1960, Nigeria has become one of the largest oil producing countries in the 
world and the national economy is dependent on the petroleum industry, generating 85% of government 
revenue and over 90% of export earnings in 2006. [3]  Driven mainly by rising oil prices, GDP growth since 
2008 has been relatively strong ranging from 6 to 8.4%, and in 2010, GDP per capita was US$ 1222, 
categorising the country as a lower middle income country according to the World Bank. [4]  However, 
Nigeria’s oil wealth has not been well distributed throughout the population, and large income inequality 
persists.  For example, despite generating over one-fifth of the national GDP in 2006, the petroleum industry 
only employed a small fraction of the national labour force, while agriculture, in comparison, employed 
nearly 70% of the population and accounted for around 40% of GDP [3], and in 2004, nearly two-thirds of 
Nigerians were living on less than $1.25 per day (adjusted for purchasing power parity). [4]   
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To address these issues, Nigeria launched its National and State Economic Empowerment and Development 
Strategies (NEEDS and SEEDS) for growth and poverty reduction in 2004 based on 3 pillars: (i) empowering 
people and improving social service delivery; (ii) improving the private sector and focusing on non-oil 
growth; and (iii) changing the way government works and improving governance.  This was followed in 2007 
by President Yar’Adua’s 7-point agenda focussing on power and energy; food security and agriculture; 
wealth creation and employment, mass transportation, land reforms; security; qualitative and functional 
education and pursuance of the rule of law. [3]  While some progress has been made since 2004, particularly 
in the areas of economic stability, procurement and financial sector reform, much remains to be done.  For 
example, from 2009 to 2010, Nigeria’s ranking in the World Bank’s ease of doing business report decreased 
from 134th to 137th out of a list of 183 countries [4], and was ranked 134th out of 178 countries in 
Transparency International’s Corruption Perception Index in 2010. [5] Nigeria has some of the worst social 
indicators: in 2009, life expectancy at birth was 51 years, nearly 1 out of every 6 children died under the age 
of 5, and only 61% of the adult population was literate. [4] 
 
Pharmaceutical Sector 
The pharmaceutical sector in Nigeria is regulated by two government agencies: the National Agency for Food 
and Drug Administration and Control (NAFDAC), which is responsible for regulating the importation, export, 
manufacture, advertisement, distribution, sale and use of drugs, cosmetics, medical devices, bottled water 
and chemicals, and undertakes activities to ensure the quality and safety of such products, including 
registration and inspection of imported, exported and manufactured products [6]; while the Pharmacists 
Council of Nigeria (PCN) regulates the practice of pharmacy in all regards, including training and registering 
of pharmacists and pharmacy technicians, and the inspection and monitoring of premises where 
pharmaceutical activities, such as dispensing, wholesaling and retailing, take place. [7]  The PCN issues 
different licenses for the manufacturing, importing, wholesaling (for authorised distributors and wholesalers) 
and retailing of pharmaceuticals; and in order obtain each of these licenses, the business must be registered 
with the Corporate Affairs Commission and a registered pharmacist must be attached to the business as the 
superintendent pharmacist, or as an owner in the case of retail pharmacies. [7]  Drug shops that are only 
permitted to sell a limited range of over-the-counter medicines (OTCs), known as Proprietary Patent 
Medicine Vendors (PPMVs), must also obtain a license from the PCN in order to operate; however, PPMVs 
are not required to have a pharmacist attached to the business. 
 
Pharmaceutical manufacturing in Nigeria is relatively well developed and in 2008 there were 140 licensed 
drug manufacturers, and given the market size, importing is also common with 286 licensed drug importers 
in 2008.  Domestic manufacturers may also import medicines when they do not possess the necessary 
capacity to produce them (e.g. injectables) or repackage imported products to suit the local market. [8] The 
headquarters of drug manufacturers and importers are located throughout the country, but are particularly 
concentrated in the major commercial centres near Lagos, Ibadan, Ilorin, Kano and Onitsha.  Among the local 
manufacturers, over 100 of these were licensed to produce an antimalarial medication in 2008, and of these, 
10 were licensed to produce an ACT, although none are WHO prequalified. [8] Several multinational 
pharmaceutical manufacturers have local subsidiaries that import their antimalarial products (e.g. Ipca 
Laboratories Ltd [India], Sanofi-Aventis [Morocco], Novartis [China, USA]), while other foreign manufacturers 
may deal with one or more local importers.  While importers are free to change their suppliers, importers 
commonly act as sole agents for products manufactured outside of Nigeria, a tendency supported by the 
stringent product registration requirements (i.e. foreign manufacturers must be certified by NAFDAC prior to 
supplying drugs for import which can be a lengthy process), the amount of time that it takes to develop a 
relationship with the supplier, and the amount of investment that goes into developing the local market for 
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the imported product. [8]  Duties are generally imposed on imported pharmaceuticals; however there are 
exceptions for medication for HIV, malaria and tuberculosis. [9]  
 
In the public sector, procurement and distribution in Nigeria is both centralized and decentralized.  Most 
medicines are procured and stored by the individual health care institutions, while medication for HIV, 
malaria and tuberculosis are centrally procured and distributed from the federal Central Medical Store 
(CMS). [9]  Each state also has its own CMS, and procures and stores pharmaceuticals for their public 
facilities. [10]  Private sector distribution is handled through pharmaceutical wholesalers, of which there 
were 616 businesses licensed to do so in 2008; although it is widely accepted that unlicensed wholesalers 
play a very significant role in drug distribution at this level of the supply chain. [8]  Wholesaling activity is 
typically concentrated within commercial hubs at the regional or state level, with notable pharmaceutical 
markets located in Lagos, Onitsha, Kano and Ibadan. The use of vertically integrated distribution 
infrastructure and third-party logistics service providers is common among manufacturers and importers to 
achieve wide geographic coverage of their products, which is enhanced through the pervasive use of sales 
representatives deployed, not only for product detailing, but also for order taking and delivery. [8]  In terms 
of retailing and dispensing, the 2009 ACTwatch Outlet Survey revealed that the most common type of 
outlets stocking antimalarials was PPMVs (81%), followed by general retailers (9%) then public health 
facilities (4%).  Registered pharmacies were the least common formal source of antimalarials at 1%. [11]  
Regulatory capacity is limited in Nigeria, and as such, prescription only medicines are sometimes sold over-
the-counter without a prescription. [9] It is also widely recognised that, while only authorized to stock OTC 
medicines, PPMVs usually stock all types of drugs, diagnose, prescribe, dispense and even administer 
injections. [10]  Drug counterfeits also pose a significant challenge to regulation of the sector and patient 
safety. [12]  Lastly, the prices of medicines are not regulated in Nigeria. [9] 
 
Health System 
In the public sector, delivery of tertiary, secondary and primary health services are the responsibility of one 
of the administrative levels of government: federal, state, and local, respectively.  At the primary level, care 
in the public sector is provided by a network of PHC facilities, comprised of health posts, clinics and 
dispensaries providing basic services, and PHC centres providing higher level services. [2]  Public health 
facilities charge registration fees, and in most states, medicines are financed through drug-revolving-fund 
schemes; therefore, medicines are financed by patients, usually out-of-pocket – however, in most states 
there are exemptions for selected groups and medicines (including ACTs). [10] The private health system 
consists of a mix of for-profit and not-for profit health facilities across all levels of care, as well as 
pharmacies, PPMVs and drug sellers that also provide diagnostic and treatment services.  The role of the 
private sector in providing health services is large:  For example, in the period 1999-2001, although only 2% 
of tertiary hospitals were private, 72% of secondary and 35% of primary health facilities were private. A 
household survey carried out by FMOH found that 56% of respondents who were ill in the previous two 
weeks purchased drugs from a private seller compared to 35% who obtained drugs from a public health 
facility. [2] 
 
In 2009, total health expenditure was 5.8% of GDP, translating to approximately US$ 69 per capita.  Of this, 
36.3% was paid by various levels of government (constituting 6.4% of total government expenditures that 
year); while the remaining 63.7% private expenditure came mostly out-of-pocket.  Spending on health 
covered by private insurance is very low and accounted for 3% of private expenditure. [13]  Total 
pharmaceutical expenditure in 2007 accounted for 5.4% of total health expenditure and 0.35% of GDP, 
amounting to approximately US$ 3.88 per capita. [9] 
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Malaria Epidemiology and Control Strategies 
Nigeria’s geographic location creates a suitable climate for malaria transmission throughout the entire 
country, apart for the mountainous areas located in Plateau State.  There are five ecological strata from 
South to North (mangrove swamps, rain forest, Guinea-, Sudan- and Sahel-savannah) where the duration of 
the transmission season decreases from perennial in most of the South to only 3 months or less in the 
border region with Chad. [2]  The dominant malaria parasite species is Plasmodium falciparum. 
 
It is estimated that approximately 30% of the population live in areas of high to very high transmission 
intensity and 67% in the moderate transmission zone and that a total of 70-110 million clinical cases occur 
each year.  In 2009, the number of deaths due to malaria was estimated to be around 300 000 among 
children under 5 years of age and malaria was responsible for 11% of all maternal deaths. [2] 
 
Malaria control activities to date have focussed on integrated vector management targeting children and 
mothers, with a strong emphasis on improving ITN coverage.  Efforts to improve ITN coverage have 
consisted mainly of free public distribution of long-lasting insecticide treated nets (LLIN), often integrated 
with other public health activities such as antenatal care, immunisation campaigns, and mass drug 
administration for diseases like onchocerciasis.  Improving coverage via distribution through the private 
commercial sector is another key strategy and has been done in several ways, such as subsidised and at-cost 
sales through social marketing organisations, and also voucher schemes which have been supported by 
NetMark and Exxon Mobile.  Based on the 2010 Malaria Indicator Survey, the current national coverage of 
households with at least one net is estimated at 44% and that of ITN coverage at 42% [14]; and coverage 
targets for 2013 as set out in the National Malaria Strategic Plan 2009-2013 are for 85%. [2]  Indoor residual 
spraying (IRS) does not play an important role in malaria control, although some pilot studies using IRS are 
taking place.  Another strategy for malaria control that figures in the national plan is intermittent preventive 
treatment of pregnant women (IPTp).  A national survey conducted in 2008 showed that 58% of pregnant 
women received ANC services from a skilled provider and 53% of these attended at least twice. [15]  
However, although 40% of women who recently gave birth took antimalarials for prevention during 
pregnancy, only 13% received this treatment during an antenatal visit. [14]  
 
National Treatment Policy 
In 2004, artemether-lumefantrine (AL) 20mg/120mg was adopted to replace chloroquine as the first-line 
treatment for uncomplicated malaria by the National Malaria Control Program (NMCP), and 
artesunate+amodiaquine (ASAQ) was included at a later date as an alternative.  According to the treatment 
policy, severe malaria is to be treated at tertiary health facilities while lower level health facilities may 
provide pre-referral treatment with artesunate suppositories. The approved treatment for severe malaria is 
quinine, artesunate or artemether injection. Oral artemisinin monotherapy has been banned in Nigeria since 
2006. [16] 
 
The treatment policy includes parasitological confirmation for suspected cases of malaria where facilities 
exist, with the exception of children under-five who should be treated based on clinical diagnosis.  
Parasitological confirmation is not required as a pre-condition for initiating treatment for those with 
suspected severe malaria.  The treatment policy acknowledges that laboratory facilities are not available at 
primary level and that they may not be available even at secondary level.  The policy states that use of RDTs 
is desirable where microscopy does not exist; however, RDTs are not readily available. [17]  For example, the 
2009 ACTwatch Outlet Survey found that, although diagnostic testing was available at 27.5% of public health 
facilities, 86.1% of private not-for profit health facilities and at 37.0% of private for-profit health facilities, 
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this consisted of mostly microscopy, and that the availability of any diagnostic tests in other types of outlets, 
such as pharmacies and drug stores, was less than 3%. [11]   
 
Antimalarial Treatment Distribution and Delivery 
Patients access treatment for malaria through the public sector and a diverse range of private sector outlets. 
ACTs are to be provided free of charge via the public sector and non-profit health facilities, including 
community health extension workers (CHEW) associated with public health facilities. [9]  A subsidy 
programme run by SFH and funded by the Global Fund has made child doses of ASAQ available since 2008 
through private sector health facilities, pharmacies and PPMVs in 18 of the 36 states and the Federal Capital 
Territory. These products, with brand names Arsuamoon and Larimal, were sold for a wholesale purchase 
price of 5 NGN (US$ 0.03) per treatment with an approved retail price set at 30 NGN (US$ 0.20). However, 
the subsidised Arsuamoon and Larimal products distributed under this programme had identical packaging 
to their non-subsidised commercial equivalents that were being concurrently sold by private sector 
wholesalers and retailers across the entire country at considerably higher prices. Therefore, to ensure that 
the target retail price was achieved and also to minimise leakage of the subsidised product outside of 
programme areas and target retail outlet types, SFH chose to bypass private sector wholesalers and 
distributed these subsidised products directly to target outlets in the participating states from their own 
warehouses and only in limited quantities (e.g. PPMVs were permitted to purchase 2 packages from SFH per 
transaction). Subsidised ASAQ was also distributed through several of civil society partners (Africare Nigeria, 
Errand Express, Planned Parenthood Federation of Nigeria) strategically selected by SFH in order to improve 
coverage in underserviced rural areas.  
 
In 2007, a total of 17.5 million doses of ACTs (AL and ASAQ) were distributed in the public and NGO sectors 
or sold in the private sector at subsidised prices through SFH.  While this represents notable progress 
compared to 2006 when less than half of this volume was distributed, it still only provided treatment for 
about 25% of the estimated number of malaria cases. [2]  In 2005, 0.1% of under-5 children were promptly 
treated with ACT [2], and by 2010, this figure had increased to 3.2% [14]-- both well below the coverage 
target of 80%.  As such, considerable effort has been made to improve access to treatment at community 
level as part of the broader aim to improve overall case management.  This has included pilot studies on 
home management of malaria fever and on the use of role-model mothers (RMM), and the World Bank 
Malaria Control Booster Project that focuses not only on improving access to prevention, treatment and 
RDTs in the public sector in 7 states, but also improving procurement and logistics, monitoring and 
evaluation, and coordination across programmes and jurisdictions. [18]  
 
However, as in many other developing countries, care for a large proportion of febrile children in Nigeria is 
first sought from the private sector.  The ACTwatch Household Survey conducted in 2009 found that 45.5% 
of such care was initially sought from private providers at health facilities (7.1%), pharmacies or PPMVs 
(27.1%). [19]  The informal market is believed to play a very significant role in the distribution and delivery of 
antimalarials in Nigeria. [8]   
 
Malaria Financing 
Funds from Round 4 of the Global Fund to fight AIDS, Tuberculosis and Malaria were used to fund the private 
sector subsidy program for ASAQ described above since 2008.  A $500 million Global Fund Round 8 grant 
was signed in 2008, and additional funds were made available through the World Bank Malaria Booster 
Program and the UK Department for International Development (DfID). The Round 8 grant will support 
prompt and effective treatment of malaria with ACTs, use of sulphadoxine-pyrimethamine (SP) for 
intermittent preventive treatment (IPT) of malaria in pregnancy, use of RDTs and microscopy, and integrated 
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vector management.  From 2009, Nigeria has also been approved to receive US$ 300 million in additional 
Global Fund malaria-related grants through Round 9 in support of the Strategic Plan 2009-2013; however, a 
significant proportion of these funds have been reallocated to activities related to Nigeria’s participation in 
the pilot phase of the Affordable Medicines Facility – malaria (AMFm), particularly to cover a range of 
‘supporting interventions’.  Nigeria signed the Global Fund grant to participate in the AMFm in 2010, which is 
intended to increase the distribution and uptake of ACTs through the private, public, and not-for-profit 
channels by lowering the cost of ACTs to the end user through a high-level subsidy mechanism. 
 
The U.S. Agency for International Development (USAID) has also been supporting malaria control efforts in 
Nigeria for more than ten years, with funding increasing steadily over the years from US$ 7 million in 2007 to 
$18 million in 2010. In 2011, Nigeria will also begin receiving funds from the US President’s Malaria Initiative, 
and the amount of funding requested during the initial year is US$ 48.5 million. [20]  
 
3. Methods 
3.1. Scope of the supply chain survey 
The Supply Chain structured survey was conducted amongst wholesalers who operated in the private 
commercial distribution chain that served the antimalarial drug retailers described in the first round of the 
ACTwatch Outlet Survey conducted in 2008.  The term ‘private commercial sector distribution chain’ refers 
to any type of supplier (public or private) who served private commercial outlets as well as private suppliers 
who served public and NGO outlets.  This allows any transactions between public, NGO and private 
commercial sectors to be noted.  Public suppliers of public outlets are, however, not included because much 
more is already known about the structure of the public sector chain compared to that of the private 
commercial sector.  The focus is on suppliers who operate from the point where commodities leave the 
factory gate or port of entry down to those directly supplying retailers.  See Figure 3.1 for a representation 
of the wholesale supplier interactions that are captured by the Supply Chain survey. 
 
The supply chain survey explored the distribution chain for antimalarials, comprising artemisinin-
combination therapy or ACT (e.g. artemether-lumefantrine), artemisinin monotherapies or AMT (e.g. 
artesunate, artemether) and non-artemisinin therapies or nAT (e.g. chloroquine, quinine), and including all 
formulations (tablets, syrups, injectables, etc.), whether they are used for inpatient or outpatient care.  It 
excluded complementary products, such as drips, water and syringes.  It also explored the availability, sales 
volumes, and mark-ups on RDTs sold in the distribution chain under study, but excluded microscopy services.  
The latter were excluded because of the wide range of different products used in providing microscopy 
services and the problems in distinguishing those used for malaria diagnosis from those with other purposes. 
 
The structured survey was cross-sectional and collected data on the structure of the private commercial 
sector supply chain for antimalarial drugs, wholesaler characteristics and business practices, wholesale 
outlet licensing and inspection, wholesaler knowledge, qualifications and training; and wholesale availability, 
purchase prices and mark-ups for antimalarials and RDTs.  In order to provide a complete description of the 
supply chain for antimalarial drugs, the report also presents retail-level data on antimalarial purchase prices 
and mark-ups that were collected during the second round of the ACTwatch Outlet Survey by SFH Nigeria 
between August and September 2009. 
 
 
 15 
3.2. Sampling & data collection procedures 
3.2.1. Overview of sampling and data collection during the ACTwatch Outlet Survey 
For the purpose of the first ACTwatch Outlet Survey, Nigeria was divided into 4 geographically-defined 
strata: Lower North, South East, Upper North, South West.  In each stratum, 19 sub-districts were randomly 
sampled using a probability proportional to size (PPS) approach through which more populated sub-districts 
had a higher chance of being selected.  Sub-districts were created by aggregating existing electoral 
enumeration areas such that the combined area covered a population size of approximately 10,000 to 
15,000 inhabitants.  In each sub-district, a census of all public and private outlets that had the potential to 
sell or distribute antimalarials was conducted and outlets that stocked antimalarials at the time of the survey 
or in the past 3 months were invited to participate in the Outlet Survey.  In order to estimate antimalarial 
availability and price across different outlet types, this sample was supplemented by a booster sample that 
included all public sector outlets and registered pharmacies operating in the district within which the 
sampled sub-district was situated.  The use of a booster sample is a common procedure across all ACTwatch 
outlet surveys to ensure adequate representation of relatively rare but important antimalarial provider 
types.  All registered pharmacies and public sector outlets (e.g. health posts, health centres, hospitals) in the 
entire district which were not in the selected sub-district itself that stocked antimalarials were identified 
through a census in the relevant districts.   
 
The first Outlet Survey was conducted in the sampled sub-districts and booster districts by SFH Nigeria in 
December 2008, with a second outlet survey conducted between August and September 2009.  The Outlet 
Surveys collected data on antimalarial drug availability, sales volumes and selling prices, retail outlet and 
shopkeeper characteristics (antimalarials stocked, other drugs stocked, number of staff, education, health-
related qualifications, registration status, GPS co-ordinates) as well as other areas of importance for the 
Supply Chain Survey, including each retailer’s two top supply sources for antimalarials (name, location, 
provider type, whether they distribute, collect or both) and antimalarial wholesale purchase prices. 
 
 
 
 
 
Figure 3.1:  Antimalarial 
wholesale supplier 
interactions captured by 
the Supply Chain Study 
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3.2.2. Sampling and data collection procedures for the ACTwatch Supply Chain survey 
The Supply Chain survey was implemented by LSHTM, with support from SFH Nigeria, after the first round of 
the Outlet Survey, from July to September 2009.  A random sample of 20 sub-districts from the Outlet 
Survey’s 76 sampled sub-districts (5 from each of the 4 strata) was used to create a list of all antimalarial 
wholesale sources mentioned by retailers as their two top antimalarial wholesale sources (termed the 
“terminal wholesalers”) during the Outlet Survey administered by SFH Nigeria.1  All these terminal 
wholesalers that could be located were visited and invited to participate in the Supply Chain survey. 
Wholesalers were eligible to participate if they met the following screening criteria: they had either an 
antimalarial or RDT in stock at the time of interview, or they reported having stocked either antimalarials or 
RDTs in the three months prior to interview.  During the interview, eligible wholesalers were also asked 
about their top two supply sources for antimalarials (termed the “intermediate-1” wholesalers).  From these 
data, we created a list of all intermediate-1 wholesalers mentioned.  All these intermediate-1 wholesalers 
were visited and invited to participate in the Supply Chain survey, during which, as at previous levels, they 
were asked about their top two supply sources for antimalarials (termed the “intermediate-2” wholesalers).  
This process was repeated until the factory gate or port of entry was reached.  Some domestic antimalarial 
manufacturers also import other antimalarial products or sell antimalarials produced by other domestic 
manufacturers.2   In these cases, domestic manufacturers were treated as wholesalers for these products, 
and as such were included for interview. 
 
The Supply Chain Survey used an information sheet, a consent form, a provider questionnaire, and 
antimalarial and RDT inventory sheets.  All data collection tools were provided in English, piloted by 
members of the research team, and further revisions were made to adapt the tools to the specificities of the 
Nigerian context.  Before each interview, trained interviewers sought to speak with the most knowledgeable 
person about their antimalarial/RDT wholesale business.  They informed respondents about the study by 
providing the information sheet in English.  Interviewers stated their name, the institutions involved, aims of 
the study, nature of questions to be asked and length of the interview.  Each respondent was given the 
opportunity to ask questions at any time before, during and after the interview, and received the contact 
details of the local research coordinator.  Interviewers then invited respondents to participate in the study 
and obtained oral consent, witnessed by a member of the research team.  Interviewers emphasized that 
individual information was confidential and that no information would be passed on to regulatory 
authorities or competitors. 
 
The provider questionnaire was used for collecting data on each wholesale business’s characteristics and 
operations and on the wholesalers’ top two supply sources for antimalarials and RDTs.  Inventory sheets 
were used for collecting data for each antimalarial/RDT stocked, on brand name, generic name and strengths 
(for antimalarials), package type and size, recall of volumes sold over the week before the survey, recall of 
last purchase value and selling and purchase prices. The Supply Chain component of the ACTwatch study 
received ethical approval from the National Health Research Ethics Committee of Nigeria (reference number: 
NHREC/01/01/2007) and the LSHTM ethics review committee. 
 
                                                          
1
 Supply sources for outlets that were sampled as part of the outlet survey booster sample were excluded.  
2
 There may be horizontal trading within the supply chain, for example if a terminal wholesaler purchases their antimalarial drugs 
from another wholesaler who has also been identified from the outlet survey as a terminal wholesaler.  Where these relationships 
were identified at the wholesale level the supply chain survey was not administered again to this wholesaler, though the relationship 
was noted and accounted for in the analysis.  However, in the case where horizontal trading is identified at the retail outlet level (for 
example, a retailer identifies another retailer as the source of their antimalarials), the supply chain survey was administered to the 
source of supply, even if they have already filled in the outlet survey instrument, because the questions asked were different.   
 17 
3.3. Data analysis 
3.3.1. Classification of outlets 
A challenge in the analysis of wholesalers is their classification into sub-groups, as in practice many operate 
at several levels of the distribution chain.  We have taken 2 approaches:  
 To describe the structure of the chain, wholesalers were classified into mutually-exclusive categories 
(MECs) defined by the levels they supplied, for example, wholesalers supplying retailers only, 
wholesalers supplying retailers and terminal wholesalers only, and wholesalers supplying intermediate 
and terminal wholesalers only. 
 For analytical purposes, wholesalers were grouped into 2 broader and overlapping categories: one 
including wholesalers supplying retailers and one for wholesalers supplying wholesalers.  Some 
wholesalers may therefore be included in both analytical categories.  This second approach for 
classifying wholesalers addresses the issue of individual MECs including very few wholesalers.  
Furthermore, this approach reflects the actual operations of the distribution chain. 
In order to get a complete picture of the distribution chain for antimalarial drugs, data relevant to the retail 
level are also presented for 5 mutually exclusive categories of retailers:  pharmacies, private health facilities 
(includes both for-profit and not-for-profit facilities), PPMVs/drug stores, other private outlet types (includes 
retail stores, such as supermarkets, and also itinerant vendors), and public health facilities (also includes 
community health workers).  See appendix 6.2 for descriptions of the type of retailers included in these 
categories. 
 
3.3.2. Calculation of sales volumes 
Antimalarial volumes and price data are reported for 5 dosage forms, namely tablets, oral liquids, 
injectables3, suppositories and granules; and 3 antimalarial categories4 namely artemisinin-based 
combination therapy (ACT), artemisinin monotherapies (AMT) and non-artemisinin therapies (nAT).  ACTs 
were further sub-divided into WHO-prequalified ACT and non-WHO-prequalified ACT. 
 
Antimalarial volumes were calculated on the basis of an adult equivalent treatment dose (AETD).  An AETD 
was defined as the number of milligrams (mg) of an antimalarial drug needed to treat a 60 kg adult (refer to 
Appendix 6.3 for data used during calculation of AETDs).  The number of mg/kg used to calculate one AETD 
was defined as what was, at the time of the study, recommended for a particular drug combination in the 
treatment guidelines for uncomplicated malaria in areas of low drug resistance issued by the WHO.  Where 
WHO treatment guidelines did not exist, AETDs were based on product manufacturers’ treatment guidelines.  
In the case of ACTs as the treatment consists of 2 or more active antimalarial ingredients packaged together 
(either co-formulated or co-blistered), the strength of the artemisinin-based component was used as the 
principal ingredient for the AETD calculations.  Information collected on both the medicine strength and unit 
size, as listed on the product packaging, was then used to calculate the number of AETDs contained in each 
unit.  The median number of antimalarial doses reported to have been sold during the week preceding the 
survey was estimated for each antimalarial category for each wholesaler category.  Estimates were 
calculated by first summing the number of AETDs sold for the different antimalarial categories at each 
wholesale outlet and then by taking the median across the wholesaler category.  Similar estimates were 
made for RDT sales volumes in each wholesaler category. 
                                                          
3
 Liquid and powder injectables form a single category. 
4
 Antimalarial drugs intended for prophylaxis and drug combinations not used to treat malaria but that contain an ingredient with 
antimalarial action were excluded from analysis.  
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For wholesale outlets that stocked antimalarials/RDTs and for which some or all sales volumes were missing, 
missing values were imputed using the STATA 11 command mi impute pmm5.  For wholesale outlets with no 
antimalarials of a given category in stock at the time of the survey, sales volumes over the past week were 
assumed to be null.  For wholesale outlets without information about the type of antimalarials stocked 
(because of refusals to participate in the study or to provide information on the type of antimalarials stocked 
or because of interrupted interviews), sales volumes were treated as missing.  In the case of an outlet not 
stocking antimalarials, sales volumes were set to zero. 
 
3.3.3. Calculation of purchase prices and mark-ups 
Wholesale purchase prices and mark-ups were calculated using data collected during the ACTwatch Supply 
Chain Survey.  Because it is common for wholesalers to vary their prices with the volumes they sell, 
minimum, mid-point and maximum mark-ups were calculated using data on maximum and minimum selling 
price charged for one unit by wholesalers.  The wholesale maximum percentage mark-up was calculated as 
the difference between the highest wholesale selling price (that is the price of the minimum volume sold 
wholesale) and the wholesale purchase price, divided by the wholesale purchase price.  The wholesale 
minimum mark-up was calculated as the difference between lowest wholesale selling price (that is the 
minimum price charged for wholesale sales) and wholesale purchase price, divided by wholesale purchase 
price.  The wholesale percent mid mark-up was calculated as:  
 
[[[(highest selling price)+(lowest selling price)]/2]- (wholesale purchase price)]/(wholesale purchase price) 
 
Retail purchase prices and mark-ups were calculated using price data collected during the ACTwatch Outlet 
Survey 2009.  When calculating summary estimates for purchase prices and mark-ups, there was a need to 
weight outlet survey data to allow for (a) the difference in sampling probabilities due to variation in the size 
of strata, (b) the oversampling for the booster, and (c) the sampling strategy which involves a census of retail 
outlets in the sub-districts of varying size selected using PPS. Stratum-specific weights were calculated for 
each sub-district sampled in each of the four strata.  Appendix 6.4 provides a detailed description of the 
calculations performed and weights used. 
 
Retail percentage mark-ups were calculated for each product as the difference between selling price and 
purchase price, divided by purchase price.  For both retail and wholesale observations, absolute mark-ups 
per AETD were calculated for each product as selling price minus purchase price.  Data were collected in 
local currencies and converted to their US$ equivalent using the average interbank rate during the data 
collection period.6 
 
 
 
 
 
                                                          
5
 A technique used for imputing missing values of one continuous variable whose distribution is skewed.  Missing values (e.g. in the 
case of an outlet stocking antimalarials and with the antimalarial type identified in the audit sheet but for which sales volume data 
were missing) were imputed using covariates related to provider/outlet and product characteristics.  Five imputations were 
conducted and their mean imputed to the missing values.   
6
 Outlet Survey data collection took place between 4 August and 16 September 2009 and an average exchange rate of 1 US$ to 
155.566 Nigeria Naira during the data collection period was used for the calculation of retail absolute mark-ups.  Supply Chain Survey 
data collection took place between 18 July to 8 September 2009 and an average exchange rate of 1 US$ to 154.892 Nigeria Naira 
during the data collection period was used for the calculation of wholesale absolute mark-ups.  Historical exchange rates averaged 
over the specified periods were obtained from http://www.oanda.com/currency/historical-rates.  
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3.3.4. Summary measures 
Indicators are reported using proportions or for continuous variables, the median and inter-quartile range 
(IQR), which are relevant for describing distributions likely to be skewed.  Given that for analytical purposes, 
wholesalers were classified into overlapping categories (i.e. wholesalers supplying retailers and wholesalers 
supplying wholesalers), it was not possible to conduct statistical tests of difference between the 2 groups.  
 
4. Results 
4.1. Overview of the sample 
A total of 150 supply sources were mentioned by retailers sampled in the 20 selected Outlet Survey sub-
districts, of which 3 (2.0%) referred to a local manufacturer, and 2 (1.3%) were listed with a general location 
but without a supplier name. 82 (54.7%) mentioned a supplier in a main market in large commercial centres 
in Bauchi, Ibadan, Kano, Lagos and Onitsha, of which 19 mentioned only the market name and no specific 
supplier (4 in Kano, 6 in Lagos, 9 in Onitsha).  One supplier (0.7%) mentioned by a private sector retailer was 
‘government drug stores’. For the remaining 125 supply sources, other uncertainties around supplier 
business names or locations were clarified by calling suppliers, and in the absence of contact numbers, 
advice on location was sought from local informants, including SFH staff members and data collectors who 
had participated in the Outlet Survey data collection.  This process identified 8 (5.3%) duplicates, leaving a 
total of 117 suppliers to form the sample of terminal wholesalers.  To account for the 19 supplier mentions 
that listed only a main market, additional wholesaler interviews were attempted in the 3 locations (Kano, 
Lagos and Onitsha), 13 of which were successful.  Out of the 130 total attempted interviews among terminal 
level wholesalers, 1 was ineligible to participate as they did not meet the screening criteria, 7 could not be 
located, and a suitable respondent was not available following several visits in 3 wholesalers.  Among those 
eligible to participate, 15 refused and 2 stopped the interview before completing all sections of the provider 
questionnaire or the inventory of antimalarials, leaving 104 terminal wholesalers with completed or partially 
interviews. 
 
All 102 terminal wholesalers who were successfully interviewed were asked about their top two supply 
sources for antimalarials.  From a total of 182 wholesaler mentions, 6 referred to foreign manufacturers 
(which are beyond the scope of this study), and 59 referred to local manufacturers (17 of which were 
supplied via sales representatives or depots).  Of these 59 mentions of local manufacturers, 32 referred to 
local manufacturers that only sell their own domestically produced antimalarials (and are therefore beyond 
the scope of this study), while the remaining 27 mentioned local manufacturers that either imported 
antimalarials or sold antimalarials produced by other local manufacturers.  The remaining 144 wholesaler 
mentions referred to 76 unique wholesale businesses, called intermediate-1 wholesalers as they supplied 
terminal wholesalers.  Of these 76 identified intermediate-1 wholesalers, 8 had already been identified at 
the terminal level (as they also supplied retailers included in the Outlet Survey sample directly), one of which 
refused. As such, an interview was not re-administered to these 8 wholesalers.  Of the remaining 68 
intermediate-1 wholesalers, interviews were successfully administered to 33, 1 was partially administered, 
12 refused, 8 could not be located, 1 had closed permanently, a suitable respondent not available following 
several attempts in 9, and 4 did not meet inclusion criteria as they did not stock antimalarials or RDTs at any 
point in the 3 months preceding the interview.   
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From the 41 intermediate-1 wholesalers (the 7 interviewed at terminal level and 34 newly interviewed), we 
obtained 56 total mentions for intermediate-2 wholesalers of which 16 were foreign manufacturers and 6 
referred to local manufacturers that only sell their own domestically produced antimalarials.  The remaining 
34 mentions referred to 21 unique wholesalers, of which 5 were local manufacturers that either imported 
antimalarials or sold antimalarials produced by other local manufacturers (2 of which supplied the 
wholesaler via sales representatives or depots).  14 of these had already been identified at previous levels 
(with whom 9 interviews were completed), leaving 7 newly identified wholesalers at this level.  Of these 7 
intermediate-2 wholesalers, interviews were completed with 2, another 4 could not be located, and a 
suitable respondent was not available in one.  These 11 intermediate-2 wholesalers (9 interviewed at a 
previous level and 2 newly interviewed) produced a total of 11 mentions for intermediate-3 wholesalers.  All 
but one of these were foreign manufacturers, and the 1 remaining mention referred to a wholesaler that 
had already been identified and interviewed at a previous level.  Therefore, no new interviews were 
conducted at this level and the top of the chain was deemed to have been reached, with a total of 205 
wholesalers that sold antimalarials identified and 140 interviews conducted (137 completed and 3 partially 
completed). (Table 4.1) 
 
 
Table 4.1: Overview of the wholesalers sampled and interviewed 
Levels of  
operation 
Initial 
Sample 
Size 
Number 
identified at 
previous 
level(s) 
Number of 
refusals
1
 
Number of 
duplicates
2
 
Number 
not 
eligible
3
 
Number not 
interviewed 
for other 
reasons
4
 
Number 
not found 
Number of 
interviews 
conducted
5
 
Total - - 27 8 5 14 19 140 
Terminal 130 - 15 8 1 3 7 104 
Intermediate-1 76 8 12 0 4 10 8 34 
Intermediate-2 21 14 0 0 0 1 4 2 
Intermediate-3
6
 1 1 0 0 0 0 0 0 
1: One refusal at intermediate-1 and 5 at intermediate-2 level occurred at previous levels.  2: Wholesalers included in the initial sample and found to be 
duplicates prior to data collection.  3: Outlets not stocking antimalarials or RDTs at the time of the interview or in the preceding 3 months.  4: At terminal 
level, a suitable respondent was not available in 3 wholesalers; at intermediate-1 level, 1 had closed permanently, a suitable respondent not available in 9 
wholesalers; at intermediate-2 level, a suitable respondent not available in 1 wholesaler.  5: At terminal level, 8 additional interviews were conducted across 
markets in Kano, Lagos and Onitsha to account for the 19 supplier mentions in these locations that did not mention a specific business; partial interviews 
conducted with 2 wholesalers at terminal level (i.e. 2 partial and 102 completed interviews) and with 1 wholesaler at intermediate-1 level (i.e. 1 partial and 
33 completed interviews).  6: This is the top of the chain, defined as the level at which wholesalers who were reported to supply intermediate-2 wholesalers 
mentioned only manufacturers as top supply sources for antimalarials. In the ACTwatch protocol, this level was referred to as the primary level where 
wholesalers who receive supplies directly from manufacturers operated. 
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4.2. Structure of the private commercial sector distribution chain for antimalarial 
drugs 
 Markets in large commercial centres in Nigeria are an important source of antimalarial supplies, where 
high concentrations of businesses engage in medicine wholesaling and retailing.  Many private retail 
outlets throughout the country mentioned these markets in several large urban areas as their two top 
suppliers of antimalarials: from those retailers who purchased in Onitsha, 89.5% of all supplier mentions 
were in markets; 57% in Bauchi; 100% in Kano; 46.4% in Lagos; and 58.8% in Ibadan.  At the wholesale 
level, 12.8% of all supplier mentions referred to businesses located in markets.  While most supplier 
mentions specifically named a business operating in a market, at the retail level 22.0% of all supplier 
mentions only mentioned the market name rather than a specific business.  
 In terms of transactions between sectors, no wholesalers reported a public source as one of their two 
top suppliers of antimalarials; however, one private outlet reported a public source (public sector 
medicines stores distributing antimalarials purchased through the Global Fund) as one of their two top 
suppliers of antimalarials, and 2 public facilities surveyed at outlet level mentioned a private sector 
source as one of their two top antimalarial suppliers.  In addition, one retailer (a private health facility) 
and 5 wholesalers mentioned the NGO, the Society for Family Health (SFH), as one of their two top 
antimalarial suppliers; however, all of the identified wholesalers who mentioned SFH as a supplier were 
also retailing antimalarials. 
 The structure of the private commercial sector distribution chain for antimalarials in Nigeria is depicted 
in Figures 4.2.1 and 4.2.2.  In Figure 4.2.1, each red dot represents a mutually exclusive group of 
wholesalers which are defined by the specific supply chain levels that each wholesaler group serves 
(these interactions are shown by the array of arrows emanating from each dot).  The relative size of each 
group is shown in the attached percentage. The dashed line from manufacturer to retailer indicates that 
a few retailers purchased antimalarials directly from manufacturers, although this was rare (2% of all 
suppliers mentioned by retailers were local drug manufacturers). Figure 4.2.2 depicts how wholesalers 
have been grouped into the overlapping analytical categories used throughout this report, while Table 
4.2 shows how these analytical categories have been derived from the mutually exclusive categories 
depicted in Figure 4.2.1. 
 The observed maximum number of steps from manufacturers’ factory gate to retail outlet is 5: 
manufacturer  intermediate-3 wholesaler  intermediate-2 wholesaler  intermediate-1 wholesaler 
 terminal wholesaler  retailer. 
 Among all wholesalers surveyed, regardless of supply chain level, 63.4% were observed to sell directly to 
retailers, nearly all of whom (93.8%) sold only to retailers. 
 Nearly half (40.5%) of all wholesalers were observed to sell to other wholesalers.  Most of these 
wholesalers (90.4%) were observed to sell only to other wholesalers, and only 3.9% of all wholesalers 
were observed to sell to both wholesalers and retailers. 
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Figure 4.2.1: Representation of the antimalarial 
distribution chain showing interactions between 
supply chain levels by mutually exclusive 
wholesaler category 
 
 
 
WS: wholesaler;  INT: intermediate 
Figure 4.2.2: Representation of the 
antimalarial distribution chain showing the 
overlap between wholesaler categories used 
for analysis 
  
 
 
 
 
 
Table 4.2: Defining analytical categories from mutually exclusive wholesaler categories 
WHOLESALER 
CATEGORIES 
Total 
number 
identified 
MUTUALLY EXCLUSIVE CATEGORIES ANALYTICAL CATEGORIES 
Supplies 
 int 1 
Supplies 
 int 1 & 
terminal 
Supplies  
 int 1, 
terminal 
& retailer 
Supplies 
retailer 
Supplies 
terminal 
Supplies 
terminal 
& retailer 
Supplies 
 int 2, int 1, 
terminal & 
retailer 
Supply 
Retailers 
Supply 
Wholesalers 
% of WS 100% 3.4% 5.4% 1.0% 59.5% 27.8% 2.4% 0.5% 63.4% 40.5% 
(N) (205) (7) (11) (2) (122) (57) (5) (1) (130) (83) 
 
WS: wholesaler, int: intermediate wholesaler 
Note: this table presents the number of wholesalers identified which exceeds those interviewed
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4.3. Wholesaler characteristics and business practices 
4.3.1. Years in operation, outlet size and range of products sold 
 Wholesalers had been in operation for a median of 8 years; however, this varied considerably.  Wholesale 
businesses also ranged in size from those supplying retailers with a median of 5 workers (IQR 3-7) to 
those supplying other wholesalers with a median of 8.5 workers (IQR 5-25). 
 Less than half of all wholesalers (43.6%) sold other products alongside pharmaceuticals.  The most 
common consumer goods stocked by all wholesalers were toiletries (27.9%), bednets (25.7%) and food 
and drinks (15.0%). 
 
Table 4.3.1: Years in operation, outlet size and range of products sold 
 WHOLESALER CATEGORIES 
CHARACTERISTICS 
ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
Years in operation Median 8 9.5 8 
 IQR 5-17 5-17 5-18 
 (N) (129) (38) (97) 
Number of people working at outlet Median 5 8.5 5 
 IQR 3-8 5-25 3-7 
 (N) (134) (38) (103) 
Sells other products in addition to 
pharmaceuticals1 
% 43.6 30.2 49.0 
(N) (140) (43) (104) 
IQR: Inter-quartile Range; 1: other products included toiletries, mobile air time, cigarettes, prepared food, groceries and/or 
household goods (including bednets) 
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4.3.2. Wholesalers’ customers, delivery activities and credit facilities 
Wholesalers mentioned a broad range of antimalarial customers, mainly in the private sector, and included 
customers in other countries.  More than half of all wholesalers mentioned that one of their top two suppliers 
was an antimalarial manufacturer, although more wholesalers operating at higher levels of the distribution 
chain did so than wholesalers operating at lower levels of the chain (i.e. those that supply retailers). 
 
Customer types 
 Wholesalers mentioned a broad range of antimalarial customer types in both private and public sectors; 
however, the most frequently mentioned customers were in the private sector: PPMVs or drug stores 
(mentioned by 90.5%), pharmacies (79.1%), private clinics, health centres or dispensaries (78.7%), 
private hospitals (77.4%), and other drug wholesalers (74.1%).  Very few wholesalers (2.9%) reported 
selling antimalarials to government or non-governmental organisations. 
 More wholesalers supplying retailers compared to those supplying other wholesalers were observed to 
sell antimalarials to retail customers (80.6% vs. 25.6%), PPMVs or drug stores (96.1% vs. 78.1%), and 
general retailers, such as grocery stores (63.1% vs. 52.4%). Conversely, a higher proportion of 
wholesalers supplying other wholesalers reported selling antimalarials to private hospitals (81.0% vs. 
76.5%), public hospitals (83.3% vs. 62.4%), and to customers in other countries (28.6% vs. 10.7%). 
 Of those who reported selling antimalarials to customers in other countries, 45.5% had customers in 
Cameroon, 40.9% in Niger, 22.7% in Chad, and 18.2% each in Benin, Ghana and Mali.  
 
 Business practices 
 Nearly a half (44.2%) of wholesalers supplying other wholesalers reported importing antimalarials, while 
only 3.9% of wholesalers supplying retailers imported antimalarials. 
 More than half (55.8%) of all wholesalers identified a manufacturer as one of their two top antimalarial 
suppliers; but the proportion was higher among wholesalers supplying other wholesalers compared to 
those supplying retailers (77.8% vs. 50.0%) 
 5.6% of wholesalers supplying other wholesalers received orders from at least one of their two top 
antimalarial suppliers through a manufacturer sales representative or one of their regional depots, while 
a higher proportion of those supplying retailers (14.0%) reported doing so. 
 Of those wholesalers that reported a manufacturer as one of their two top antimalarial suppliers, 20.8% 
reported a foreign manufacturer as one of their top two antimalarial sources, while 79.2% were supplied 
by domestic manufacturers. 
 Of all the wholesalers that named a domestic manufacturer as at least one of their top two antimalarial 
suppliers, 21.1% of these reported that their orders were arranged through a sales representative or 
received from a depot (either owned by the manufacturer or operated by a third-party logistics 
company) located within their region.  There were 2 instances of vertically integrated wholesale supply 
chains, where a domestic manufacturer operated one or more subsidiary wholesalers in regional 
commercial centres in different parts of the country. These subsidiary wholesalers were supplied 
exclusively by the ‘parent’ manufacturer.  
 A third (32.6%) of all wholesalers reported delivering antimalarials to their customers; but more than 
half (59.5%) of the wholesalers supplying other wholesalers delivered compared to under a quarter 
(22.3%) among those supplying retailers. 
 More than three quarters of all wholesalers interviewed (77.9%) had offered credit to customers in the 
past 3 months, offering a median of 14 days credit (IQR 7-30).   
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Table 4.3.2: Wholesalers’ Customers, Delivery Activities and Credit facilities 
 
 
 WHOLESALER CATEGORIES 
ANTIMALARIAL CUSTOMER TYPES 
ALL 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
Retail Customers (e.g. patients, care-takers) % 35.5 25.6 80.6 
 (N) (139) (43) (103) 
Retail Outlets 
Pharmacies % 79.1 83.7 78.6 
 (N) (139) (43) (103) 
PPMVS or drug stores % 90.5 78.1 96.1 
 (N) (137) (41) (103) 
General retailers (grocery stores, etc.)1 % 59.4 52.4 63.1 
 (N) (138) (42) (103) 
Public clinics, health centres or dispensaries % 72.3 73.8 72.6 
 (N) (137) (42) (102) 
Private clinics, health centres or dispensaries % 78.7 76.2 81.2 
 (N) (136) (42) (101) 
Public hospitals % 67.7 83.3 62.4 
 (N) (136) (42) (101) 
Private hospitals % 77.4 81.0 76.5 
 (N) (137) (42) (102) 
Wholesale Outlets 
Drug wholesalers % 74.1 88.42 69.9 
 (N) (139) (43) (103) 
General wholesalers1 % 51.5 72.1 44.1 
 (N) (138) (43) (102) 
Customers in Other Countries % 15.9 28.6 10.7 
 (N) (138) (42) (103) 
BUSINESS PRACTICES 
SUPPLY 
WHOLESALERS 
SUPPLY 
WHOLESALERS 
SUPPLY 
RETAILERS 
Import antimalarial drugs % 14.5 44.2 3.9 
(N) (138) (43) (102) 
Buy directly from antimalarial manufacturers 
(as one of two top antimalarial suppliers) 
% 55.8 77.8 50.0 
(N) (129) (36) (100) 
Supplied via sales representative or depot 
(from one of two top antimalarial suppliers) 
% 12.4 5.6 14.0 
(N) (129) (36) (100) 
Deliver antimalarials to customers % 32.6 59.5 22.3 
(N) (138) (42) (103) 
Provided credit to customers in the past 3 
months 
% 77.9 77.5 78.6 
(N) (136) (40) (103) 
Most common terms of credit offered in the 
past 3 months (number of days) 
Median 14 24.5 14 
IQR 7-30 14-30 7-30 
(N) (102) (28) (79) 
1:  Some wholesalers interviewed may have understood the question asked to mean customers for ‘any medicines’ and not specifically 
antimalarials, or perhaps customers that buy ‘any medicines for the management of malaria’, which may include antipyretics, 
vitamins, etc. that are commonly sold by general retailers.  2: Five of the 43 wholesalers in this category reported that they did not 
supply drug wholesalers; however, during the supply chain survey, a wholesale respondent identified this particular wholesaler as one 
of their top two supply sources for antimalarials. To remain consistent across indicators, we have chosen to report this indicator as 
88.4% rather than 100.0% based on the information reported by the suppliers rather than their customers. 
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4.4. Licensing & inspection 
Although wholesalers and retailers of pharmaceutical goods in Nigeria should be licensed through the 
Pharmacists Council of Nigeria, many were found to not hold the required licenses.  However, around 70% 
reported that a pharmaceutical inspector had visited them in the past year. 
 
 Among all wholesalers interviewed, 45.3% reported having a wholesale pharmacy license; however, this 
figure was higher among wholesalers supplying other wholesalers (73.2%) than among those supplying 
retailers (39.6%). However, an up-to-date wholesale pharmacy licence was observed in only 8.0% of all 
wholesalers interviewed.  A higher proportion of wholesalers operating at higher levels of the supply 
chain (i.e. wholesalers supplying wholesalers) were observed to have an up-to-date wholesale license 
compared to wholesalers supplying retailers (19.1% vs. 3.9%). 
 Less than a fifth (15.9%) of all wholesalers interviewed reported having a retail pharmacy license, 
although 26.8% of wholesalers did report having a PPMV license, which only permits the retail of 
selected over-the-counter medicines; possession of a PPMV licence was reported by 35.0% of 
wholesalers supplying retailers and only 4.8% of those supplying other wholesalers.  In addition, 19.6% 
of all wholesalers reported having only a PPMV license. 
 Few wholesalers (10.8%) were observed to have the required registration with the Corporate Affairs 
Commission.  
 Possession of a pharmacy import license was reported by more wholesalers operating at higher levels of 
the supply chain compared to those supplying retailers (48.8% vs. 5.8%); these figures were similar to 
the number of wholesalers who reported importing antimalarials: 44.2% of wholesalers supplying 
wholesalers vs. 3.9% of wholesalers supplying retailers. 
 Nearly two-thirds (73.8%) of wholesalers interviewed reported that they had been visited by a 
pharmaceutical inspector in the past year. 
 
Table 4.4: Licensing & Inspection 
 WHOLESALER CATEGORIES 
REGISTRATION STATUS 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
Reported having a license allowing wholesale of 
pharmaceuticals 
% 45.3 73.2 39.6 
(N) (137) (41) (103) 
Reported having a retail pharmacy license  
% 15.9 16.7 16.5 
(N) (138) (42) (103) 
Reported having a PPMV license % 26.8 4.8 35.0 
 (N) (138) (42) (103) 
Reported having an import license % 16.8 48.8 5.8 
 (N) (137) (41) (103) 
Reported having a manufacturer license %  11.6 31.0 4.9 
 (N) (138) (42) (103) 
Any up-to-date license from the PCN was 
observed
1
 
%  8.7 19.1 4.9 
(N) (138) (42) (103) 
An up-to-date wholesale license from the PCN was 
observed 
%  8.0 19.1 3.9 
(N) (138) (42) (103) 
Corporate Affairs Commission registration 
certificate was observed
2
 
%  10.8 12.5 10.3 
(N) (130) (40) (97) 
Reported they had been visited by a 
pharmaceutical inspector in the past year 
% 71.2 76.3 69.0 
(N) (132) (38) (100) 
1: This license may be either a retail or wholesale pharmacy license, but not a PPMV license intended solely for the retail of specific 
OTC drugs; 2: A certificate of registration with the Corporate Affairs Commission  is a requirement by the PCN in order to operate a 
wholesale or retail pharmacy, or pharmaceutical manufacturing; this requirement, however, does not apply to operate a PPMV. 
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4.5. Knowledge, qualifications and training 
Knowledge of ACTs and malaria-related training received were generally found to be similar across 
wholesaler categories, despite the fact more wholesalers operating at higher levels of the distribution chain 
employed staff members with health qualifications than wholesalers at lower levels of the chain. 
 
 Half of all wholesalers interviewed (53.6%) were able to correctly identify AL or ASAQ as the government 
recommended first-line treatment for uncomplicated Pf malaria; 34.1% of all wholesalers responded 
that they did not know the recommended treatment. 
 However, the proportion of wholesalers identifying an ACT as the most effective medication for treating 
uncomplicated malaria was slightly lower (45.7% for children and 43.5% for adults).  AL was most 
commonly mentioned as the most effective antimalarial among all wholesalers (22.5% for children and 
24.6% for adults) and ASAQ was mentioned as most effective for adults by 11.6% of wholesalers and for 
children by 18.8% of wholesalers.  However, 20.3% of all wholesalers mentioned SP as the most effective 
treatment of malaria for adults, making it the second most commonly mentioned ‘most effective’ 
antimalarial.  Among all wholesalers, 12.3% of all wholesalers mentioned chloroquine as the most 
effective treatment of malaria for children. 
 Two thirds (62.8%) of all wholesalers reported employing staff with health qualifications; the proportion 
of wholesalers supplying other wholesalers that reported employing such staff was higher than among 
those supplying retailers (85.7% vs. 54.9%). 
 Among all wholesalers who reported employing a member of staff with a health qualification, the most 
commonly reported health qualifications were pharmacists (88.4%), followed by pharmacy 
technicians/assistants (22.1%) and nurses/midwives (22.1%). 
 The percentage of wholesalers who indicated that staff had participated in in-service training related to 
malaria treatment in the past 2 years was low (16.9% of all wholesalers interviewed). 
 
Table 4.5: Wholesalers’ knowledge, qualifications and training 
 WHOLESALER CATEGORIES 
HEALTH QUALIFICATIONS, TRAINING AND KNOWLEDGE 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
Employ a member of staff with health 
qualifications1 
% 62.8 85.7 54.9 
(N) (137) (42) (102) 
Employ staff who participated in in-service training 
related to malaria treatment in the past 2 years 
% 16.9 13.9 17.0 
(N) (124) (36) (94) 
Identify any ACT as the most effective medication 
for treating uncomplicated Pf malaria in adults 
% 43.5 57.1 39.8 
(N) (138) (42) (103) 
Identify any ACT as the most effective medication 
for treating uncomplicated Pf malaria in children 
% 45.7 47.6 44.7 
(N) (138) (42) (103) 
Correctly identify the government recommended 
first line treatment for uncomplicated Pf malaria 
% 53.6 54.8 53.4 
(N) (138) (42) (103) 
1: Health qualifications included pharmacist, pharmacy technician, pharmacy assistant, medical doctor, nurse, 
midwife, clinical officer 
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4.6. Storage of antimalarial drugs 
Wholesalers were observed to practice good storage practices. 
 
 All wholesalers were observed to store antimalarials in a dry area and out of direct sunlight; although a 
slightly lower percentage was observed to keep them off the floor (97.0%). 
 97.0% of all wholesalers met each of the specified conditions for good storage of antimalarials (in a dry 
area, out of direct sunlight and off the floor). 
 
Table 4.6: Wholesalers’ storage practices 
 WHOLESALER CATEGORIES 
STORAGE 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
Store antimalarials in a dry area % 100.0 100.0 100.0 
(N) (100) (23) (83) 
Store antimalarials out of direct sunlight % 100.0 100.0 100.0 
(N) (100) (23) (83) 
Store antimalarials off the floor % 97.0 100.0 96.4 
(N) (100) (23) (83) 
Store antimalarials in a dry area, out of direct 
sunlight & off the floor 
% 97.0 100.0 96.4 
(N) (100) (23) (83) 
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4.7. Availability of antimalarials & RDTs 
Although more than three-quarters of all wholesalers surveyed (86.2%) had an ACT in stock at the time of the 
interview, only 53.6% of stocked WHO prequalified ACTs. Oral AMTs were observed to be in stock in 72.5% of 
wholesalers while few RDTs were stocked (3.6%). 
 
 A higher proportion of all wholesalers had non-WHO prequalified ACTs in stock (76.1%) than WHO 
prequalified ACTs (53.6%); only a third (35.7%) of wholesalers operating at higher levels of the supply 
chain stocked WHO prequalified ACTs. 
 More than three-quarters of all wholesalers (85.2%) reported having had at least one ACT in stock 
throughout the three month period prior to interview 
 A similar proportion of all wholesalers (83.3%) stocked AL and/or ASAQ, the recommended first-line 
treatments for uncomplicated Pf malaria; 64.5% stocked AL and 71.0% stocked ASAQ.  In addition, 40.6% 
of all wholesalers stocked the brands of ASAQ, Larimal or Arsuamoon; however, a lower proportion 
stocked these products in states participating in the subsidy programme (26 of 84, or 30.1%) and in 
states not participating in the subsidy programme (30 of 54, or 55.6%). 
 Oral AMTs were observed to be in stock in 72.5% of all wholesalers and nATs in 87.7% of all wholesalers; 
although, fewer wholesalers supplying other wholesalers were observed to stock oral AMTs and nATs 
compared to those wholesalers supplying retailers (AMTs: 47.2% vs. 81.6%, respectively; nATS: 69.0% vs. 
94.2%, respectively). Most AMT products observed (79.5%) were in oral dosage form. 
 The most frequently observed antimalarials were the first-line antimalarial, AL (accounting for 16.0% of 
all antimalarial products stocked by wholesalers), chloroquine (15.7%), SP (15.5%), and ASAQ (14.7%); 
the next three most frequently observed antimalarials were all AMTs (artesunate, dihydroartemisinin, 
artemether) that together accounted for 17.4% of all antimalarial products stocked by wholesalers, all of 
which in oral dosage form. 
 AL and ASAQ accounted for the majority of ACT products observed to be stocked by all wholesalers 
(41.0% and 37.7%, respectively); the next most frequently observed ACT was dihydroartemisinin-
piperaquine (DHA-PP), accounting for 8.3% of all ACT products stocked.  A fifth (20.1%) of all the ASAQ 
products observed to be stocked by all wholesalers were the brands Larimal or Arsuamoon 
 RDTs were stocked by only 3.6% of all wholesalers. 
Table 4.7: Antimalarial & RDT availability 
 WHOLESALER CATEGORIES 
AVAILABILITY 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
Had antimalarials in stock  % 98.6 95.2 100.0 
(N) (138) (42) (103) 
Had ACT in stock  % 86.2 88.1 86.4 
(N) (138) (42) (103) 
Always had at least one ACT in stock over the past 
3 months 
% 85.2 87.5 85.3 
(N) (135) (38) (102) 
Had WHO prequalified ACT in stock % 53.6 35.7 61.2 
(N) (138) (42) (103) 
Had non-WHO prequalified ACT in stock % 76.1 76.2 76.7 
(N) (138) (42) (103) 
Had oral AMT in stock % 72.5 47.6 81.6 
(N) (138) (42) (103) 
Had non-oral AMT in stock % 33.3 33.3 34.0 
(N) (138) (42) (103) 
Had nAT in stock % 87.7 69.0 94.2 
(N) (138) (42) (103) 
Had RDT in stock  % 3.6 7.1 1.9 
(N) (138) (42) (103) 
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4.8. Sales volumes of antimalarials and RDTs 
Typical wholesale volumes were largest for non-artemisinin therapies, followed by ACTs; however, the typical 
sales volume for non-artemisinin therapies was four times larger than for ACTs.  Moreover, the typical sales 
volume for non-WHO prequalified ACTs was 20 times higher than for prequalified ACTs.  SP was the top 
selling antimalarial for nearly half of all wholesalers.  
 
Among all wholesalers (n=136; Table 4.8.1): 
 The median number of adult equivalent treatment doses (AETDs) sold the week preceding the survey 
was highest for nATs (562.9, IQR: 163.6-2006.6), followed by ACTs (137.9, IQR 12.8-794.0) and AMTs 
(42.0, IQR 3.8-272.1).  Looking more closely at ACTs, the median number of AETDs sold of non-WHO 
prequalified ACTs (94.0, IQR: 2.6-556.4) was higher than for WHO prequalified ACTs (4.8, IQR: 0.0-60.0). 
 86.8% reported selling an ACT during the week preceding the survey; this figure was 77.9% for AMTs and 
89.0% for nATs. 
 More AETDs were sold as tablets than any other dosage form across antimalarial drug categories, 
including AMTs where there has been a ban in place for the oral form of the drug since 2006.  Relative to 
ACTs and AMTs, high median volumes of oral liquid nATs were sold by wholesalers.  The volumes of 
granule and suppository dosage forms sold were very low:  median sales volumes among all wholesalers 
stocking any antimalarial across all antimalarial categories were 0 (IQR 0-0).  However, 19.9% of all 
wholesalers did report selling an ACT in granule dosage form during the week preceding the survey.  See 
Appendix 6.1 for additional tables on sales volumes of suppository and granule dosage forms. 
 
Among wholesalers stocking the corresponding product category (Table 4.8.2): 
 Among wholesalers who stocked ASAQ products branded as either Larimal or Arsuamoon  (n=56), the 
median number of AETDs sold of these products was 18.8 (IQR 8.9-66.5); volumes of these products sold 
were slightly higher among wholesalers located in states participating in the subsidy programme (21.3 
AETDs, IQR 5.0-131.0) than those in states not participating (15.7 AETDs, IQR 9.0-45.0). 
 Among all wholesalers who had antimalarials in stock at the time of interview (n=135), the top selling 
antimalarial was AL for 13.3% of wholesalers and ASAQ for 5.9% (the two recommended first-line 
treatments for uncomplicated malaria), while SP was the top selling antimalarial for 45.2% and 
chloroquine for 19.3%.7 
 Compared to wholesalers supplying retailers, the top selling antimalarial for wholesalers supplying other 
wholesalers was more likely to be AL (18.0% vs. 12.6% for wholesalers supplying retailers) and ASAQ 
(15.4% vs. 1.9%); however, SP was the top selling antimalarial for more wholesalers than any other 
antimalarial: 38.5% of wholesalers supplying other wholesalers, and 48.5% of wholesalers supplying 
retailers.   
 WHO prequalified ACTs were sold by fewer wholesalers (54.4%) than non-WHO prequalified ACTs 
(75.7%), and when wholesalers stocked and sold these types of ACTs, the median volume of WHO 
prequalified ACTs being sold (51.9 AETDs, IQR: 13.5-222.5) was only a quarter of the typical volumes 
being sold for non-WHO prequalified ACTs (193.5 AETDs, IQR: 45.4-760.4).  This difference was even 
more pronounced at higher levels of the supply chain (Table 4.8.2). 
 RDTs were not commonly stocked by wholesalers. Among those who did stock RDTs, the volume of tests 
sold varied both within and across supply chain levels.  Among those who stocked RDTs, the median 
number of tests sold during the week preceding the survey was 315 (IQR 30-600) among wholesalers 
supplying wholesalers, while wholesalers supplying retailers sold a median 25 tests (IQR 0-50).
                                                          
7
The analysis of the top selling antimalarials used sales volumes data collected for each antimalarial in stock at the time of the 
survey:  in each outlet and for each antimalarial stocked, wholesalers were asked to recall the quantity they had sold during the week 
preceding the survey 
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Table 4.8.1: Median number of AETDs & RDTs sold during the week preceding the survey (all wholesalers) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
N=136
3
 N=40
 
N=103 
All ACT All Median 137.9 787.4 114.8 
IQR 12.8-794.0 117.4-4633.1 8.4-530.8 
Tablet Median 120.0 730.4 97.2 
IQR 11.8-730.4 103.2-4200.0 7.0-518.9 
Oral liquid Median 0.0 0.0 0.0 
IQR 0.0-26.3 0.0-42.3 0.0-26.3 
WHO prequalified 
ACT 
All products 
were tablets 
Median 4.8 0.0 9.0 
IQR 0.0-60.0 0.0-86.6 0.0-60.0 
Non-WHO 
prequalified ACT 
All Median 94.0 418.0 70.2 
IQR 2.6-556.4 4.9-2266.7 2.6-374.0 
Tablet Median 83.0 400.2 50.0 
IQR 2.6-520.3 4.9-2135.4 2.6-313.3 
Oral liquid Median 0.0 0.0 0.0 
IQR 0.0-26.3 0.0-42.3 0.0-26.3 
AMT All Median 42.0 165.8 38.7 
IQR 3.8-272.1 0.0-934.9 11.0-206.4 
Tablet Median 28.1 0.0 31.3 
IQR 0.0-155.3 0.0-309.5 5.6-121.9 
Oral liquid Median 1.0 0.0 1.7 
IQR 0.0-17.3 0.0-35.0 0.0-18.3 
Injectable Median 0.0 0.0 0.0 
IQR 0.0-2.6 0.0-16.5 0.0-1.7 
nAT All Median 562.9 1207.3 555.5 
IQR 163.6-2006.6 0.0-8144.7 166.7-1635.3 
Tablet Median 392.3 607.4 398.6 
IQR 90.4-1649.2 0.0-7795.9 120.0-1359.9 
Oral liquid Median 26.8 0.0 32.0 
IQR 0.0-101.8 0.0-67.7 0.0-106.4 
Injectable Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
 ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
N=142 N=46 N=103 
RDT
4
 (per unit)  Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria; 2 The values for median number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, 
oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of 
these product types were observed during the audit, results are not presented separately for these categories in this table, but are instead 
provided in the appendix. 3 For antimalarials: there were a total of 136 wholesalers with antimalarial sales volumes (reported or imputed or 
set as null if did not stock). Note on imputation process for antimalarial sales volumes: during the study, 205 wholesalers were identified, of 
which 137 were interviewed successfully.  Of the remaining, 3 were partially interviewed, 27 refused, 33 were not screened because a 
respondent was not available, the business had closed or could not be found, and 5 did not stock antimalarials at the time of the survey or 
during the three months prior to the visit (Table 1). These 68 wholesalers were excluded from the volumes analysis. Two additional 
wholesalers did not stock antimalarials at the time of interview but did so in the three months prior to interview, so their sales volumes 
were set as 0 for all antimalarial categories.  Overall, there were a total of 2531 antimalarials audited, and 903 (35.7%) had missing sales 
volumes that were imputed using the mi impute pmm command.  4 For RDTs, of the 136 wholesalers completely interviewed or from whom 
stocking information was collected, 5 reported stocking RDT and inventory data were collected on 6 observed products.  Of these, 
information on sales volume was not provided for 1 product from 1 wholesaler; however imputation was not performed as there were too 
few observations to reliably perform linear regression.  Sales volumes were set as missing for the 1 wholesaler who reported stocking RDTs 
but from whom inventory data were not collected.  Therefore for RDTs, median sales volumes at the level supplying retail outlets are 
estimated based on the sample of 5 products from 4 wholesalers for which volumes were not missing. 
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Table 4.8.2: Median number of AETDs & RDTs sold during the week preceding the survey (among wholesalers 
stocking corresponding antimalarial drug category/RDT at the time of the survey) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES
3
 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
All ACT All Median 200.0 853.2 140.9 
IQR 49.8-890.3 162.5-6807.9 35.1-715.5 
(n) (118) (36) (89) 
Tablet Median 200.0 810.0 129.3 
IQR 47.9-821.8 160.0-6587.9 28.8-605.7 
(n) (118) (36) (89) 
Oral liquid Median 31.3 74.0 28.1 
IQR 8.9-93.8 26.4-269.7 7.5-74.2 
(n) (59) (15) (50) 
WHO 
prequalified 
ACT 
All products were 
tablets 
Median 51.9 138.0 47.5 
IQR 13.5-222.5 50.0-798.3 12.5-184.1 
(n) (74) (15) (63) 
Non-WHO 
prequalified 
ACT 
All Median 193.5 809.7 136.9 
IQR 45.4-760.4 200.0-4426.3 30.6-557.9 
(n) (103) (30) (79) 
Tablet Median 162.5 746.5 114.8 
IQR 36.7-722.8 200.0-4000.0 24.3-518.9 
(n) (103) (30) (79) 
Oral liquid Median 31.3 74.0 28.1 
IQR 8.9-93.8 26.4-269.7 7.5-74.2 
(n) (59) (15) (50) 
AMT All Median 90.8 667.6 61.6 
IQR 31.5-333.8 257.1-3424.3 25.0-265.4 
(n) (107) (23) (88) 
Tablet Median 66.7 309.5 51.3 
IQR 25.0-272.5 125.0-730.0 22.5-171.9 
(n) (95) (20) (79) 
Oral liquid Median 15.0 66.7 10.8 
IQR 3.3-46.9 16.0-385.0 2.6-34.8 
(n) (75) (15) (64) 
Injectable Median 14.1 25.2 6.9 
IQR 3.3-60.5 16.3-2014.7 1.7-43.9 
(n) (45) (14) (34) 
nAT All Median 840.0 2207.9 563.3 
IQR 261.7-2149.3 1049.9-14032.1 218.7-1777.3 
(n) (121) (29) (97) 
Tablet Median 579.0 2966.7 451.3 
IQR 166.7-1800.0 300.0-16676.5 150.0-1463.0 
(n) (117) (27) (95) 
Oral liquid Median 54.5 145.3 45.6 
IQR 26.7-228.8 46.1-961.0 23.0-161.6 
(n) (91) (16) (78) 
Injectable Median 91.6 91.6 63.0 
IQR 15.4-177.2 63.0-285.7 8.7-161.3 
(n) (40) (10) (31) 
RDT (units) Median 40 315 25 
IQR 30-50 30-600 0-50 
(n) (4) (2) (2) 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria.  2 The values for median number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, 
oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of 
these product types were observed during the audit, results are not presented separately for these categories in this table, but are instead 
provided in the appendix. 3 (n) is the number of wholesalers at a given level who stocked antimalarials for corresponding drug category or 
who stocked RDT. 
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4.9. Purchase price of antimalarials and RDTs 
Purchase price is the price paid by businesses (i.e. wholesalers or outlets) for their most recent purchase of an 
antimalarial product from their suppliers, and is reported in terms of the median price (in US dollars) per AETD.  
Because of the varied nature of wholesaler transactions (e.g. wholesalers may vary their price; antimalarials may pass 
through a number of wholesalers before reaching an outlet), wholesale purchase prices are indicative of the purchase 
prices paid by wholesalers in general, rather than at specific levels of the supply chain.  Retail purchase prices, however, 
reflect the antimalarial purchase prices paid by specific outlet types to their suppliers. 
 
Among all wholesalers, median purchase prices per AETD were highest for AMTs (US$ 4.13, IQR: 2.07-9.92), 
followed by ACTs (US$ 3.55, IQR: 2.39-5.34) and nATs (US$ 0.53, IQR: 0.26-1.21).  Tablets comprise a high 
proportion of all observed products in each drug category; and considering tablet dosage forms only, 
wholesalers purchased ACTs at a median price of US$ 3.10 per AETD, US$ 2.07 for AMT, and US$ 0.35 for 
nATs.  Of the few RDTs observed at the wholesaler level, the median price was $0.71 per test. 
 
 Median purchase prices paid for AMTs and nATs by wholesalers supplying other wholesalers were 
observed to be higher than the prices paid by those supplying retailers, because, for both categories, 
wholesalers supplying other wholesalers tended to stock a greater proportion of the more expensive 
non-tablet dosage forms (i.e. oral liquids and injectables).  A similar pattern was also observed with the 
median purchase prices for WHO prequalified ACTs (all of which were in tablet form).  However in this 
case, the particular brand of ASAQ, Larimal, comprised a higher proportion of observed products among 
wholesalers supplying retailers compared to those supplying other wholesalers (46.2% vs. 38.2%); also, 
the median purchase price paid for Larimal was lower among wholesalers supplying retailers (US$ 2.07 
vs. US$ 2.55). 
 At retail level, median purchase prices for ACTs ranged from US$ 2.70 (IQR 0.26-4.18) in private health 
facilities to US$ 3.99 (IQR 2.44-6.60) in pharmacies; for AMT, purchase prices ranged from US$ 2.47 (IQR 
2.47-2.88) in private health facilities to US$ 7.42 (IQR 2.19-13.88) in pharmacies; and for nATs, purchase 
prices ranged from US$ 0.55 (IQR 0.29-0.80) in other private outlets, such as supermarkets, to US$ 0.96 
(IQR 0.34-9.64) in private health facilities.  Median retail purchase prices for oral AMTs were generally 
comparable to prices for ACT across dosage forms within retailer types; however among pharmacies, 
the median purchase price for AMT tablets was half of the median price for ACT tablets (US$ 1.85 vs. 
US$ 3.66). 
 Public health facilities did not tend to pay for WHO prequalified ACTs; however, they did purchase non-
WHO prequalified ACTs, AMTs and nATs; and when then did so, the median purchase prices paid tended 
to be lower than those paid by private outlets.   
 Median purchase prices per AETD for tablets were lower compared to oral liquids across all antimalarial 
types and for both wholesalers and retailers.  Injectables tended to have the highest purchase prices in 
private health facilities; however in PPMVs, drug stores and other private outlets (e.g. supermarkets), 
injectables were observed to have lower purchase prices than oral liquids at the retail level.  Median 
purchase prices for ACTs in granule form were also observed to be lower than those paid for tablets or 
oral liquids. 
 For WHO prequalified ACTs at retail level, the median purchase price paid by private health facilities 
was very low compared to the other retailer categories.  In all types of retailer, the brand of ASAQ, 
Larimal, was the most commonly observed WHO prequalified product; however, the median purchase 
price paid for this product by private health facilities (US$ 0.13, IQR 0.13-0.26) – regardless of whether it 
was a for-profit or not-for-profit facility – was considerably lower compared to pharmacies (US$ 3.09, 
IQR: 1.80-5.14) and PPMVs/drug stores (US$ 2.25, IQR: 1.16-3.09).  In turn, these differences seem to be 
driven by differences in median purchase prices for Larimal itself, which were lower among private 
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sector outlets located in states participating in the subsidy than in non-participating states: In 
pharmacies, the median purchase was US$ 2.44 (IQR 1.80-3.54) in participating states vs. US$ 5.14 (IQR 
2.25-6.43) in non-participating states; in PPMVs, US$ 1.29 (IQR 0.64-2.57) in participating states vs. vs. 
US$ 2.57 (IQR 1.80-3.86) in non-participating states; and the greatest difference was observed among 
private health facilities, where the median purchase price was US$0.13 (IQR 0.13-0.26) in participating 
states vs. US$ 4.18 (IQR 2.31-5.91) in non-participating states.  
 Regarding first-line treatments for uncomplicated Pf malaria, the median purchase price per AETD at 
wholesale level for AL (US$ 4.13, IQR 3.10-6.89) was higher than that for ASAQ (US$ 2.91, IQR 1.94-
4.65); but both were still at least 10 times higher than the median price for SP (US$ 0.29, IQR 0.21-0.61), 
the antimalarial with the highest number of AETDs distributed.  At retail level, a similar pattern was 
observed, where median purchase prices for AL ranged from US$ 3.54 (IQR 3.21-4.82) in other private 
outlets, such as supermarkets, to US$ 6.60 (IQR 3.86-6.60) in pharmacies; for ASAQ, purchase prices 
ranged from US$ 1.80 (IQR 1.71-3.34) in pharmacies to US$ 2.44 (IQR 1.83-2.57) in other private outlets, 
such as supermarkets; and for SP, purchase prices ranged from US$ 0.32 (IQR 0.26-0.64) in PPMVs/drug 
stores to US$ 0.45 (IQR 0.28-0.84) in pharmacies.  However, the median purchase price for ASAQ among 
private health facilities (US$ 0.26, IQR 0.13-0.77) was comparable to that of SP, again, due to the high 
proportion of lower-priced ASAQ product observed among this outlet type branded as Larimal. 
 In the few instances where RDTs were stocked, wholesalers at all levels of supply chain reported 
purchasing 1 RDT unit at US$ 0.71 (IQR 0.52-0.90) (data were not collected on retailer purchase prices 
for RDTs).
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Table 4.9.1 Purchase price per AETD/RDT (US$), wholesale level 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
N=136 N=40 N=103 
All ACT All Median 3.55 3.23 3.55 
IQR 2.39-5.34 2.26-4.88 2.39-5.42 
(n) (754) (119) (693) 
Tablet Median 3.10 3.03 3.16 
IQR 2.26-4.20 2.13-3.99 2.26-4.20 
(n) (597) (95) (549) 
Oral liquid Median 8.26 7.49 8.26 
IQR 6.89-10.17 6.37-10.17 7.06-9.99 
(n) (111) (14) (103) 
Granule Median 4.68 - 4.91 
IQR 2.87-9.68 - 2.91-10.33 
(n) (44) - (39) 
WHO 
prequalified ACT 
All products 
were tablets 
Median 3.87 3.91 3.68 
IQR 1.81-5.16 2.55-5.09 1.81-5.16 
(n) (107) (12) (97) 
Non WHO 
prequalified ACT 
All Median 3.55 3.10 3.55 
IQR 2.45-5.68 2.26-4.78 2.50-5.94 
(n) (647) (107) (596) 
Tablet Median 3.10 2.91 3.10 
IQR 2.26-3.94 2.13-3.74 2.26-3.94 
(n) (490) (83) (452) 
Oral liquid Median 8.26 7.49 8.26 
IQR 6.89-10.17 6.37-10.17 7.06-9.99 
(n) (111) (14) (103) 
Granule Median 4.68 - 4.91 
IQR 2.87-9.68 - 2.91-10.33 
(n) (44) - (39) 
AMT All Median 4.13 5.40 3.68 
IQR 2.07-9.92 1.96-10.33 2.07-9.92 
(n) (357) (50) (325) 
Tablet Median 2.07 1.96 2.07 
IQR 1.81-2.30 1.50-2.22 1.81-2.32 
(n) (180) (21) (167) 
Oral liquid Median 9.05 10.02 8.90 
IQR 7.17-12.78 6.78-11.30 7.36-12.78 
(n) (106) (16) (94) 
Injectable Median 14.20 7.10 15.49 
IQR 8.39-21.69 6.20-10.33 9.04-25.57 
(n) (69) (13) (62) 
nAT All Median 0.53 0.67 0.52 
IQR 0.26-1.21 0.25-2.26 0.26-1.20 
(n) (875) (110) (783) 
Tablet Median 0.35 0.42 0.34 
IQR 0.21-0.89 0.17-1.10 0.21-0.86 
(n) (496) (63) (444) 
Oral liquid Median 0.73 0.79 0.73 
IQR 0.50-1.60 0.52-3.39 0.50-1.29 
(n) (306) (36) (275) 
Injectable Median 1.01 2.26 0.58 
IQR 0.27-4.07 0.27-5.15 0.27-4.07 
(n) (70) (9) (62) 
RDT (per unit) Median 0.71 0.52 0.90 
IQR (0.52-0.90) (0.52-0.52) (0.90-0.90) 
(n) (2) (1) (1) 
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: 
Rapid diagnostic test for malaria. 2 The values for median number of AETDs sold reported for ‘all’ formulations 
include all dosage forms (tablets, suppositories, oral liquids, injectables and granules); however because so few 
wholesaler and retailers stocked suppositories, and so few of these product types were observed during the audit, 
results are not presented separately for these categories in this table, but are instead provided in the appendix. 
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Table 4.9.2 Purchase price per AETD (US$), retail level  
ANTIMALARIAL TYPE
1
 
Formulation
2
 
RETAILER CATEGORIES
3,4
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
PPMVs   
DRUG STORES 
OTHER 
PRIVATE 
OUTLETS 
PUBLIC 
HEALTH 
FACILITIES 
N=276 N=227 N=906 N=96 N=198 
All ACT All Median 3.99 2.70 2.89 3.21 0.00 
IQR 2.44-6.60 0.26-4.18 1.80-4.29 2.25-4.18 0.00-0.13 
(n) (2163) (251) (785) (39) (241) 
Tablet Median 3.66 1.61 2.89 3.21 0.00 
IQR 2.70-4.63 0.13-3.86 1.80-3.99 1.99-3.86 0.00-0.13 
(n) (1690) (189) (692) (36) (212) 
Oral liquid Median 6.60 15.91 8.40 8.57 0.00 
IQR 6.60-9.43 10.46-61.71 7.07-10.29 8.57-8.57 0.00-7.20 
(n) (336) (39) (72) (3) (26) 
Granule Median 1.71 1.71 0.90 - 0.34 
IQR 1.71-1.71 1.54-2.57 0.77-2.14 - 0.34-0.34 
(n) (120) (22) (18) - (3) 
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 4.82 0.26 2.57 3.86 0.00 
IQR 3.09-5.46 0.13-0.77 1.29-3.86 1.80-5.46 0.00-0.00 
(n) (298) (72) (334) (13) (83) 
Non WHO 
prequalified 
ACT 
All Median 3.98 4.18 3.21 3.21 0.90 
IQR 2.31-6.60 2.70-7.71 2.25-4.50 2.25-3.73 0.00-3.92 
(n) (1865) (179) (451) (26) (158) 
Tablet Median 3.54 3.86 3.09 3.21 1.36 
IQR 2.70-4.50 2.70-4.18 2.12-3.99 2.25-3.54 0.00-3.92 
(n) (1392) (117) (358) (23) (129) 
Oral liquid Median 6.60 15.91 8.40 8.57 0.00 
IQR 6.60-9.43 10.46-61.71 7.07-10.29 8.57-8.57 0.00-7.20 
(n) (336) (39) (72) (3) (26) 
Granule Median 1.71 1.71 0.90 - 0.34 
IQR 1.71-1.71 1.54-2.57 0.77-2.14 - 0.34-0.34 
(n) (120) (22) (18) - (3) 
AMT All Median 7.42 2.47 2.57 2.57 1.85 
IQR 2.19-13.88 2.47-2.88 2.12-7.33 2.47-2.93 0.00-9.26 
(n) (820) (182) (761) (34) (96) 
Tablet Median 1.85 2.47 2.37 2.47 1.85 
IQR 1.65-2.37 2.47-2.47 2.06-2.57 2.37-2.78 1.85-2.37 
(n) (442) (91) (494) (26) (42) 
Oral liquid Median 9.26 16.58 9.26 15.04 19.28 
IQR 7.42-13.88 15.43-16.58 7.33-14.66 12.34-17.36 8.85-19.28 
(n) (226) (33) (213) (8) (12) 
Injectable Median 19.28 23.14 8.49 - 9.26 
IQR 12.86-27.00 13.88-65.57 6.94-11.57 - 0.00-9.26 
(n) (149) (57) (54) - (41) 
nAT All Median 0.75 0.96 0.56 0.55 0.45 
IQR 0.39-1.37 0.34-9.64 0.29-0.85 0.29-0.80 0.00-0.96 
(n) (2165) (532) (5224) (359) (446) 
Tablet Median 0.45 0.32 0.32 0.32 0.10 
IQR 0.27-0.96 0.15-0.39 0.24-0.58 0.26-0.58 0.00-0.51 
(n) (1254) (237) (2704) (203) (245) 
Oral liquid Median 0.96 0.96 0.80 0.80 0.63 
IQR 0.72-3.21 0.80-4.32 0.64-1.12 0.64-1.08 0.48-1.12 
(n) (788) (144) (2303) (151) (98) 
Injectable Median 0.48 9.64 0.32 0.30 0.45 
IQR 0.28-1.45 9.64-9.64 0.24-0.40 0.21-0.45 0.32-1.45 
(n) (123) (151) (212) (5) (103) 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 The values for median 
number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and granules); however because so few wholesaler 
and retailers stocked suppositories, and so few of these product types were observed during the audit, results are not presented separately for these categories in this table, but 
are instead provided in the appendix. 3 As these are weighted medians, medians are not the average of the middle two ordered observations for instances where there are an 
even number of observations. 4 Private health facilities include both for-profit and not-for-profit facilities; Other private outlets include supermarkets, kiosks, itinerant medicine 
sellers (hawkers) and outlet types that do not fit into any of the mentioned outlet categories; Public health facilities includes community health workers. Note: 61 of 21,031 
(0.3%) purchase price observations (19 in pharmacies, 11 in private health facilities, 29 in PPMVs/drug stores, 2 in public health facilities) were set to missing due to mark-ups in 
excess of 1000% which were likely due to errors during data collection. Data collected by the ACTwatch Group during the Nigeria 2009 Outlet Survey. www.actwatch.info 
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4.10. Price mark-ups on antimalarials and RDTs 
4.10.1.  Percent Mark-Ups on Antimalarials and RDTs 
The percentage mark-up is calculated in general terms as the difference between the selling price and the purchase 
price, divided by the purchase price.  It captures both the costs of doing business and profit to the seller.  Because 
wholesalers vary their prices, minimum, maximum and mid mark-ups were calculated using data on minimum and 
maximum selling price charged for one unit by wholesalers.  The wholesale percent mid mark-up was calculated as the 
difference between the average wholesale selling price (i.e. the mid-point between the maximum and minimum 
wholesale selling price) and wholesale purchase price, divided by wholesale purchase price.  The retail percent mark-up 
was calculated using the retail selling price and purchase price collected during the ACTwatch Outlet Survey.
8
 
 Although wholesaler mark-ups did not vary considerably across antimalarial categories or dosage forms, 
median mid percent mark-ups were highest on nATs (25.0%, IQR 11.4-47.7), followed by AMTs (20.0%, 
IQR 10.0-37.5), then ACTs (17.6%, IQR 10.7-33.3). 
 Wholesalers supplying other wholesalers tended to apply higher median mid percent mark-ups on non-
tablet dosage forms within antimalarial categories, while wholesalers supplying retailers applied more 
consistent mark-ups across dosage forms. For example, among wholesalers supplying other wholesalers, 
the median mid percent mark-up on ACT was 16.0% for tablets, 19.6% for oral liquids and 29.4% for 
granules. 
 Wholesalers reported varying their mark-up on 61.4% of all observed products depending on the volume 
being purchased (based on the 2305 observations where mark-up data were obtained). The difference 
between the highest and lowest median mark-ups was around 11% points for ACTs, 13% points for 
AMTs, and 20% point for nATs. 
 At retail level, percent mark-ups did not vary considerably across antimalarial categories within specific 
retailer types; however, private health facilities tended to apply the highest percent mark-ups.  In 
pharmacies, median percent mark-ups ranged from 25.0-36.4%; in PPMVs/drug stores, from 22.2-40.0%; 
in other private outlets (such as supermarkets), from 21.7-33.3%; while in private health facilities, 
median percent mark-ups ranged from 39.5-66.7%. 
 Percent mark-ups on oral liquids at retail level tended to be lower than or similar to those for tablets, 
while injectables tended to have higher percent mark-ups than tablets or oral liquids in private health 
facilities.  Retail median percent mark-ups were also observed to be generally higher than those for 
wholesalers.  
 It was rare for public health facilities to report taking payments for antimalarials; however, when 
applied, the median percent mark-ups added varied considerably across dosage form and drug type. 
 Regarding first-line treatments for uncomplicated Pf malaria, median percent mark-ups for ASAQ were 
higher than those for AL both at wholesale and retail level.  At wholesale level, the median mid percent 
mark-up for ASAQ was 20.3% (IQR 12.8-37.5) and 15.0% (IQR 9.0-28.7) for AL.   At retail level, the median 
percent mark-up for ASAQ ranged from 25.0% (IQR 25.0-33.3) at pharmacies to 66.7% (IQR 57.1-500.0) 
at private health facilities; while for AL, this ranged from 12.5% (IQR 7.7-41.7) at private health facilities 
to 20.0% (IQR 15.4-38.5) at other private outlets, such as supermarkets. 
 For SP, the antimalarial with the highest number of AETDs distributed, the median mid percent mark-up 
among all wholesalers was 22.0% (IQR 11.1-42.9), while the median percent mark-up at retail level 
ranged from 25.0% (IQR 19.1-53.9) at other private outlets, such as supermarkets, to 42.9% (IQR 33.3-
50.0) at private health facilities. 
 The wholesale median mid percent mark-up on RDTs was 40.4% (IQR 23.8-57.1).
                                                          
8
 Negative percent mark-ups were recorded in several cases, for which there are several possible explanations:  (1) data collection 
errors (e.g. antimalarials bought in relatively large pack sizes and sold by the tablet were sometimes subject to errors); (2) some 
businesses may have sold products at lower prices than at which they were bought to deal with slow moving products or because the 
purchase price has increased and the business was still selling the ‘old’ product at the ‘old’ price.  
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Table 4.10.1.1: Percent price mark-ups on antimalarials and RDTs, wholesale level (%) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL WHOLESALERS  
N=136 
SUPPLY WHOLESALERS 
N=40 
SUPPLY RETAILERS  
N=103 
MID LOW HIGH MID LOW HIGH MID LOW HIGH 
All ACT All Median 17.6 14.6 20.8 16.0 12.9 20.0 16.7 14.3 20.0 
IQR 10.7-33.3 8.6-27.8 12.5-40.0 8.9-41.8 6.0-36.7 11.1-46.9 10.5-28.9 8.5-25.0 12.5-36.4 
(n)  (753)   (119)   (692)  
Tablet Median 17.6 15.1 20.6 16.0 12.7 20.0 17.1 14.4 20.0 
IQR 11.1-35.2 9.1-28.8 13.3-42.9 8.9-39.5 6.0-33.3 11.1-46.3 11.0-31.4 9.0-26.7 12.8-37.9 
(n)  (596)   (95)   (548)  
Oral liquid Median 16.7 13.1 22.2 19.6 18.8 21.0 16.3 12.5 21.2 
IQR 9.8-26.7 6.7-23.7 10.0-33.3 7.0-43.2 5.7-42.9 8.3-51.4 9.8-24.3 6.7-22.2 10.0-32.4 
(n)  (111)   (14)   (103)  
Granule Median 17.2 14.7 20.0 29.4 25.8 33.0 15.8 12.8 17.6 
IQR 10.9-26.7 8.5-25.0 13.7-33.6 11.0-51.0 8.0-50.0 14.0-52.0 10.0-22.7 8.0-22.2 12.8-25.0 
(n)  (44)   (10)   (39)  
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 18.2 16.7 21.9 21.3 20.4 22.3 18.2 16.7 21.9 
IQR 11.1-33.3 9.0-27.4 13.3-37.1 11.5-38.7 7.7-34.2 14.1-43.7 11.2-31.1 9.0-26.5 13.1-36.4 
(n)  (106)   (12)   (96)  
Non WHO 
prequalified 
ACT 
All Median 17.6 14.6 20.7 16.0 12.5 20.0 16.7 14.3 20.0 
IQR 10.5-33.3 8.6-28.6 12.5-40.7 7.9-42.9 6.0-36.8 10.0-47.4 10.4-28.8 8.3-25.0 12.5-35.8 
(n)  (647)   (107)   (596)  
Tablet Median 17.5 14.9 20.0 15.0 12.1 20.0 16.7 14.3 20.0 
IQR 11.1-35.4 9.1-29.3 13.2-42.9 7.9-40.8 6.0-33.3 10.0-46.9 10.9-31.4 8.7-26.7 12.6-38.9 
(n)  (490)   (83)   (452)  
Oral liquid Median 16.7 13.1 22.2 19.6 18.8 21.0 16.3 12.5 21.2 
IQR 9.8-26.7 6.7-23.7 10.0-33.3 7.0-43.2 5.7-42.9 8.3-51.4 9.8-24.3 6.7-22.2 10.0-32.4 
(n)  (111)   (14)   (103)  
Granule Median 17.2 14.7 20.0 29.4 25.8 33.0 15.8 12.8 17.6 
IQR 10.9-26.7 8.5-25.0 13.7-33.6 11.0-51.0 8.0-50.0 14.0-52.0 10.0-22.7 8.0-22.2 12.8-25.0 
(n)  (44)   (10)   (39)  
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ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL WHOLESALERS  
N=136 
SUPPLY WHOLESALERS 
N=40 
SUPPLY RETAILERS  
N=103 
MID LOW HIGH MID LOW HIGH MID LOW HIGH 
AMT All Median 20.0 14.3 25.0 26.7 20.8 29.9 19.0 13.6 23.1 
IQR 10.0-37.5 7.1-29.6 11.1-42.9 9.0-51.6 6.0-47.8 11.1-56.3 10.0-33.3 7.1-27.0 11.1-40.0 
(n)  (358)   (50)   (326)  
Tablet Median 22.1 14.3 27.8 22.1 15.0 27.3 21.3 14.1 27.0 
IQR 11.1-40.7 8.7-36.8 11.4-48.1 10.5-54.3 5.3-50.0 12.5-60.9 11.1-38.9 8.6-34.1 11.2-42.0 
(n)  (181)   (21)   (168)  
Oral liquid Median 14.6 12.5 18.4 20.8 17.2 24.4 14.4 12.1 18.4 
IQR 8.8-31.6 6.1-26.7 9.8-34.1 6.0-61.5 5.3-55.6 7.0-67.4 8.9-27.4 6.1-22.6 10.0-31.6 
(n)  (106)   (16)   (94)  
Injectable Median 21.4 18.4 25.5 28.6 27.0 35.1 20.8 14.4 25.0 
IQR 11.1-35.3 7.1-27.0 12.5-41.2 9.4-40.6 6.7-35.4 12.5-45.8 10.0-31.1 6.7-25.0 11.1-36.4 
(n)  (69)   (13)   (62)  
nAT All Median 25.0 18.2 33.3 27.9 20.0 32.1 25.0 18.0 31.9 
IQR 11.4-47.7 9.1-33.3 12.8-60.0 10.7-50.0 9.1-38.5 12.0-58.6 11.3-45.2 8.8-33.3 12.8-60.0 
(n)  (915)   (115)   (820)  
Tablet Median 25.0 16.7 26.7 19.6 15.5 25.0 23.8 16.7 26.3 
IQR 11.1-42.9 8.6-32.0 12.0-56.3 7.3-46.4 5.3-35.4 8.8-52.8 11.1-41.7 8.7-31.3 12.5-55.6 
(n)  (534)   (68)   (479)  
Oral liquid Median 29.2 20.0 37.5 35.8 24.9 45.5 27.3 19.4 33.3 
IQR 12.5-50.0 9.3-37.5 15.4-66.7 18.0-60.0 14.3-48.3 20.7-70.0 12.1-50.0 8.6-36.4 14.3-66.7 
(n)  (306)   (36)   (275)  
Injectable Median 25.7 21.1 33.3 26.9 23.1 28.9 25.0 21.1 33.3 
IQR 15.4-54.3 11.8-40.0 16.7-66.7 19.6-45.5 18.2-45.5 19.6-45.5 14.6-54.3 11.1-40.0 15.4-66.7 
(n)  (71)   (9)   (63)  
RDT (per unit) Median 40.4 32.7 48.2 23.8 22.5 25.0 57.1 42.9 71.4 
IQR 23.8-57.1 22.5-42.9 25.0-71.4 23.8-23.8 22.5-22.5 25.0-25.0 57.1-57.1 42.9-42.9 71.4-71.4 
(n)  (2)   (1)   (1)  
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 The values for median number of AETDs 
sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories, 
and so few of these product types were observed during the audit, results are not presented separately for these categories in this table, but are instead provided in the appendix. 
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 Table 4.10.1.2: Percent price mark-ups on antimalarials, retail level (%) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
RETAILER CATEGORIES
3,4
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
PPMVs   
DRUG STORES 
OTHER 
PRIVATE 
OUTLETS
 
PUBLIC 
HEALTH 
FACILITIES 
N=274 N=156 N=906 N=96 N=189 
All ACT 
 
All Median 25.0 41.7 22.2 29.0 0.0 
IQR 16.9-31.0 12.5-66.7 13.3-40.0 18.2-42.9 0.0-0.0 
(n) (2150) (210) (783) (39) (225) 
Tablet Median 25.0 41.7 23.8 29.0 0.0 
IQR 16.7-37.5 8.3-66.7 14.6-40.0 16.7-42.9 0.0-0.0 
(n) (1669) (159) (690) (36) (198) 
Oral liquid Median 16.9 25.0 15.4 20.0 0.0 
IQR 16.9-22.2 16.7-40.0 9.0-30.4 20.0-20.0 0.0-11.1 
(n) (333) (31) (71) (3) (24) 
Granule Median 25.0 33.3 25.0 - 150.0 
IQR 25.0-25.0 25.0-50.0 19.0-40.0 - 150.0-150.0 
(n) (131) (19) (19) - (3) 
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 28.6 66.7 33.3 33.3 0.0 
IQR 20.0-43.8 60.0-500.0 20.0-50.0 13.6-50.0 0.0-0.0 
(n) (288) (59) (332) (13) (78) 
Non WHO 
prequalified 
ACT 
All Median 25.0 25.0 19.0 28.6 0.0 
IQR 16.9-30.0 7.7-41.7 11.1-29.0 18.2-40.0 0.0-0.0 
(n) (1862) (151) (451) (26) (147) 
Tablet Median 25.0 25.0 19.0 29.0 0.0 
IQR 15.4-36.4 7.7-41.7 12.0-28.6 18.2-40.0 0.0-0.0 
(n) (1381) (100) (358) (23) (120) 
Oral liquid Median 16.9 25.0 15.4 20.0 0.0 
IQR 16.9-22.2 16.7-40.0 9.0-30.4 20.0-20.0 0.0-11.1 
(n) (333) (31) (71) (3) (24) 
Granule Median 25.0 33.3 25.0 - 150.0 
IQR 25.0-25.0 25.0-50.0 19.0-40.0 - 150.0-150.0 
(n) (131) (19) (19) - (3) 
AMT 
 
All Median 29.9 39.5 22.2 21.7 4.2 
IQR 14.3-48.9 20.0-39.5 14.3-36.4 13.6-25.0 0.0-22.2 
(n) (809) (135) (760) (34) (87) 
Tablet Median 56.3 25.0 25.0 22.8 22.2 
IQR 28.6-56.3 17.6-42.9 14.6-38.9 16.7-29.7 4.2-22.2 
(n) (438) (69) (493) (26) (37) 
Oral liquid Median 28.6 39.5 17.0 11.1 30.0 
IQR 11.1-29.9 39.5-39.5 12.5-25.0 8.3-15.4 10.0-30.0 
(n) (223) (25) (213) (8) (11) 
Injectable Median 25.0 50.0 33.3 - 11.1 
IQR 16.7-36.4 25.0-100.0 15.8-50.0 - 0.0-177.8 
(n) (145) (41) (54) - (38) 
nAT 
 
All Median 36.4 42.9 40.0 27.3 19.0 
IQR 25.0-60.0 33.3-60.0 25.0-60.0 20.0-50.0 0.0-42.9 
(n) (2140) (388) (5243) (357) (433) 
Tablet Median 36.4 50.0 40.0 25.0 0.0 
IQR 25.0-60.0 38.9-75.0 25.0-60.0 20.0-60.0 0.0-25.0 
(n) (1238) (190) (2724) (202) (242) 
Oral liquid Median 33.3 42.9 38.5 27.3 33.3 
IQR 25.0-60.0 33.3-50.0 25.0-57.9 20.0-42.9 7.1-85.7 
(n) (781) (121) (2303) (150) (94) 
Injectable Median 42.9 140.0 50.0 100.0 33.3 
IQR 33.3-50.0 140.0-185.7 25.0-100.0 33.3-185.7 0.0-50.0 
(n) (121) (77) (211) (5) (97) 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 The values for median 
number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and granules); however because so few wholesaler 
and retailers stocked suppositories, and so few of these product types were observed during the audit, results are not presented separately for these categories in this table, but 
are instead provided in the appendix. 3 As these are weighted medians, medians are not the average of the middle two ordered observations for instances where there are an 
even number of observations. 4 Private health facilities include both for-profit and not-for-profit facilities; Other private outlets include supermarkets, kiosks, itinerant medicine 
sellers (hawkers) and outlet types that do not fit into any of the mentioned outlet categories; Public health facilities includes community health workers. Note: 61 of 21,031 
(0.3%) purchase price observations (19 in pharmacies, 11 in private health facilities, 29 in PPMVs/drug stores, 2 in public health facilities) were set to missing due to mark-ups in 
excess of 1000% which were likely due to errors during data collection. Data collected by the ACTwatch Group during the Nigeria 2009 Outlet Survey. www.actwatch.info 
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4.10.2. Absolute mark-ups on antimalarials and RDTs (US$) 
The absolute mark-up is calculated in general terms as the difference between the selling price and the purchase price 
per AETD and is reported in US dollars.  As with the percent mark-up, it captures both the costs of doing business and 
profit to the seller. Because wholesalers vary their prices, minimum, maximum and mid mark-ups were calculated using 
data on minimum and maximum selling price charged per AETD by wholesalers.  The wholesale absolute mid mark-up 
was calculated as the difference between the average wholesale selling price (i.e. the mid-point between the maximum 
and minimum wholesale selling price) and wholesale purchase price.  The retail absolute mark-up was calculated using 
the retail selling price and purchase price collected during the ACTwatch Outlet Survey.  Data were collected in local 
currencies and converted to their US$ equivalent using the average interbank rate for the duration of the fieldwork 
period. 
 At wholesale level, median mid absolute mark-ups were highest on AMTs (US$ 0.87, IQR: 0.44-1.94), 
followed by ACTs (US$ 0.65, IQR: 0.39-1.29), and then nATs (US$ 0.16, IQR: 0.05-0.38), generally 
corresponding to differences in median purchase price (i.e. because percent mark-ups did not vary 
considerably across antimalarial category, higher purchase price led to higher absolute mark-ups). 
 Absolute mark-ups applied within the same antimalarial category and dosage form were not observed to 
vary considerably across different levels of the wholesale supply chain.  However, retail absolute mark-
ups tended to be higher compared to wholesale level mark-ups, which is a function of the higher 
purchase prices paid by retailers to their suppliers compared to wholesalers. 
 At retail level, median absolute mark-ups exhibited a similar pattern to that observed among 
wholesalers where they were highest on AMTs, ranging from US$ 0.62 (IQR 0.51-1.03) at other private 
outlets, such as supermarkets, to US$ 2.57 (IQR 0.62-6.56) at private health facilities; followed by ACTs, 
ranging from US$ 0.64 (IQR 0.36-1.09) at PPMVs/drug stores to US$ 0.96 (IQR 0.51-1.29) at pharmacies; 
and then by nATs, ranging from US$ 0.16 (IQR 0.10-0.26) at other private outlets, such as supermarkets, 
to US$ 0.30 (IQR 0.13-0.58) at pharmacies. 
 Private health facilities tended to have higher absolute mark-ups for AMTs and nATs compared to drug 
stores and other private outlets, such as supermarkets, because they stocked relatively more injectable 
antimalarials that other retailer types.  In addition, more than half of all observed antimalarial products 
in PPMVs/drug stores and other private outlets, such as supermarkets, were produced in Nigeria, while 
pharmacies and public health facilities stocked relatively more products imported from Europe and 
China.  However, this also partly accounts for the higher absolute mark-ups observed in these two 
retailer types. 
 Regarding first-line treatments for uncomplicated Pf malaria, absolute mark-ups tended to be higher for 
AL than ASAQ among wholesalers supplying other wholesalers (median mid absolute mark-up for AL of 
US$ 0.69 (IQR 0.23-1.39) and US$ 0.56 (0.29-1.36) for ASAQ), while there was little difference among 
wholesalers supplying retailers (AL: US$ 0.67, IQR 0.36-1.26 vs. ASAQ: US$ 0.65, IQR 0.39-1.29).  Across 
retailer types, median absolute mark-ups also tended to be higher for AL than ASAQ.  In pharmacies, the 
median absolute mark-up was US$ 1.11 (IQR 0.96-1.71) for AL vs. US$ 0.45 (IQR 0.43-0.90) for ASAQ; in 
private health facilities US$ 0.64 (IQR 0.32-1.61) for AL vs. US$ 0.64 (IQR 0.51-0.64) for ASAQ; in 
PPMVs/drug stores US$ 0.69 (IQR 0.51-1.20) for AL vs. US$ 0.64 (IQR 0.39--1.29) for ASAQ; and in other 
private outlets, such as supermarkets, $0.96 (IQR 0.64-1.37) for AL vs. US$ 0.13 (IQR 0.06-0.19). 
 For SP, the antimalarial with the highest number of AETDs distributed, the median absolute retail mark-
up was US$ 0.19 (IQR 0.11-0.32) at pharmacies, US$ 0.19 (IQR 0.13-0.26) at private health facilities, US$ 
0.16 (IQR 0.10-0.23) at PPMVs/drug stores, and US$ 0.13 (IQR 0.06-0.19) at other private outlets, such as 
supermarkets; at the wholesale level, median mid absolute mark-up was US$ 0.07 (IQR 0.02-0.21) 
among wholesaler supplying other wholesalers, and US$ 0.07 (IQR 0.03-0.16) among wholesalers 
supplying retailers. 
 The median absolute mid mark-up on RDTs was US$ 0.32 (IQR 0.25-0.39) among all wholesalers.  
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Table 4.10.2.1: Absolute price mark ups on antimalarials and RDTs, wholesale level (US$) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL WHOLESALERS  
N=136 
SUPPLY WHOLESALERS 
N=40 
SUPPLY RETAILERS  
N=103 
MID LOW HIGH MID LOW HIGH MID LOW HIGH 
All ACT All Median 0.65 0.58 0.80 0.65 0.52 0.77 0.65 0.52 0.77 
IQR 0.39-1.29 0.32-1.15 0.45-1.53 0.26-1.36 0.19-1.16 0.32-1.55 0.39-1.29 0.32-1.03 0.45-1.45 
(n)  (753)   (119)   (692)  
Tablet Median 0.61 0.52 0.65 0.52 0.39 0.65 0.56 0.45 0.65 
IQR 0.32-1.19 0.26-1.02 0.39-1.29 0.23-1.29 0.19-1.10 0.32-1.48 0.32-1.03 0.26-0.90 0.39-1.23 
(n)  (596)   (95)   (548)  
Oral liquid Median 1.45 1.21 1.72 1.53 1.38 1.68 1.38 1.08 1.72 
IQR 0.77-2.50 0.58-2.07 0.86-3.10 0.69-3.10 0.60-3.10 0.86-3.27 0.77-2.24 0.52-1.89 0.86-2.75 
(n)  (111)   (14)   (103)  
Granule Median 0.94 0.77 1.23 1.19 0.97 1.48 0.90 0.77 1.29 
IQR 0.61-1.87 0.52-1.42 0.65-2.58 0.55-3.29 0.52-3.10 0.65-3.36 0.58-1.81 0.52-1.29 0.65-2.58 
(n)  (44)   (10)   (39)  
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 0.65 0.48 0.77 0.74 0.58 0.85 0.65 0.48 0.77 
IQR 0.32-1.29 0.26-1.16 0.32-1.29 0.53-1.39 0.32-1.19 0.63-1.55 0.32-1.24 0.26-1.12 0.32-1.29 
(n)  (106)   (12)   (96)  
Non WHO 
prequalified 
ACT 
All Median 0.68 0.58 0.84 0.65 0.52 0.77 0.65 0.52 0.77 
IQR 0.39-1.36 0.32-1.14 0.45-1.55 0.26-1.36 0.19-1.16 0.32-1.55 0.39-1.29 0.32-1.03 0.45-1.48 
(n)  (647)   (107)   (596)  
Tablet Median 0.58 0.52 0.65 0.52 0.39 0.65 0.55 0.45 0.65 
IQR 0.32-1.16 0.26-0.97 0.39-1.29 0.23-1.29 0.19-1.10 0.32-1.42 0.32-0.97 0.26-0.84 0.39-1.18 
(n)  (490)   (83)   (452)  
Oral liquid Median 1.45 1.21 1.72 1.53 1.38 1.68 1.38 1.08 1.72 
IQR 0.77-2.50 0.58-2.07 0.86-3.10 0.69-3.10 0.60-3.10 0.86-3.27 0.77-2.24 0.52-1.89 0.86-2.75 
(n)  (111)   (14)   (103)  
Granule Median 0.94 0.77 1.23 1.19 0.97 1.48 0.90 0.77 1.29 
IQR 0.61-1.87 0.52-1.42 0.65-2.58 0.55-3.29 0.52-3.10 0.65-3.36 0.58-1.81 0.52-1.29 0.65-2.58 
(n)  (44)   (10)   (39)  
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ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL WHOLESALERS  
N=136 
SUPPLY WHOLESALERS 
N=40 
SUPPLY RETAILERS  
N=103 
MID LOW HIGH MID LOW HIGH MID LOW HIGH 
AMT All Median 0.87 0.72 1.03 1.03 0.75 1.25 0.83 0.68 0.97 
IQR 0.44-1.94 0.31-1.55 0.52-2.32 0.41-2.91 0.32-2.58 0.52-3.49 0.41-1.84 0.31-1.45 0.52-2.07 
(n)  (357)   (50)   (325)  
Tablet Median 0.52 0.32 0.68 0.41 0.32 0.52 0.52 0.32 0.68 
IQR 0.23-0.83 0.20-0.72 0.26-1.03 0.24-0.93 0.13-0.72 0.31-1.14 0.23-0.77 0.19-0.72 0.26-1.03 
(n)  (180)   (21)   (167)  
Oral liquid Median 1.36 1.16 1.65 2.18 1.84 2.57 1.36 1.16 1.60 
IQR 0.77-2.91 0.58-2.32 0.77-3.49 0.73-3.63 0.60-3.00 0.77-4.16 0.77-2.42 0.58-1.94 0.97-3.10 
(n)  (106)   (16)   (94)  
Injectable Median 2.97 2.32 3.62 2.52 1.94 2.58 3.24 2.32 3.74 
IQR 1.74-7.23 1.23-4.13 1.94-8.26 1.08-2.91 0.70-2.58 1.47-3.87 1.39-7.75 1.03-5.16 1.55-8.65 
(n)  (69)   (13)   (62)  
nAT All Median 0.16 0.10 0.19 0.19 0.15 0.26 0.15 0.10 0.19 
IQR 0.05-0.38 0.03-0.29 0.06-0.48 0.05-0.48 0.05-0.39 0.06-0.65 0.05-0.36 0.03-0.25 0.06-0.44 
(n)  (874)   (110)   (783)  
Tablet Median 0.10 0.06 0.12 0.13 0.09 0.13 0.08 0.06 0.10 
IQR 0.03-0.24 0.03-0.19 0.03-0.31 0.02-0.27 0.02-0.23 0.03-0.32 0.03-0.23 0.03-0.19 0.04-0.29 
(n)  (495)   (63)   (444)  
Oral liquid Median 0.25 0.16 0.32 0.42 0.29 0.51 0.24 0.16 0.32 
IQR 0.15-0.48 0.08-0.39 0.16-0.56 0.21-0.79 0.15-0.68 0.28-0.89 0.12-0.44 0.08-0.34 0.15-0.56 
(n)  (306)   (36)   (275)  
Injectable Median 0.28 0.24 0.33 0.44 0.36 0.44 0.25 0.23 0.28 
IQR 0.07-1.08 0.07-1.02 0.09-1.08 0.06-1.02 0.05-1.02 0.07-1.02 0.07-1.08 0.07-0.84 0.10-1.08 
(n)  (70)   (9)   (62)  
RDT (per unit) Median 0.32 0.12 0.52 0.12 0.12 0.12 0.52 0.52 0.52 
IQR 0.25-0.39 0.12-0.13 0.39-0.65 0.12-0.13 0.12-0.13 0.12-0.13 0.39-0.65 0.39-0.65 0.39-0.65 
(n)  (2)   (1)   (1)  
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 The values for median number of AETDs 
sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories, 
and so few of these product types were observed during the audit, results are not presented separately for these categories in this table, but are instead provided in the appendix. 
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 Table 4.10.2.2: Absolute price mark ups on antimalarials, retail level (US$) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
RETAILER CATEGORIES
3,4
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
PPMVs   
DRUG STORES 
OTHER 
PRIVATE 
OUTLETS
 
PUBLIC 
HEALTH 
FACILITIES 
N=276 N=155 N=904 N=96 N=193 
All ACT 
 
All Median 0.96 0.64 0.64 0.90 0.00 
IQR 0.51-1.29 0.43-1.29 0.36-1.09 0.64-1.29 0.00-0.00 
(n) (2135) (208) (782) (39) (225) 
Tablet Median 0.90 0.64 0.64 0.77 0.00 
IQR 0.64-1.29 0.32-0.96 0.35-1.03 0.64-1.29 0.00-0.00 
(n) (1668) (159) (690) (36) (198) 
Oral liquid Median 1.11 2.89 1.20 1.71 0.00 
IQR 1.11-2.06 1.71-4.80 0.86-1.74 1.71-1.71 0.00-0.64 
(n) (333) (31) (71) (3) (24) 
Granule Median 0.43 0.69 0.30 - 0.51 
IQR 0.43-0.43 0.43-2.57 0.17-0.43 - 0.51-0.51 
(n) (117) (17) (18) - (3) 
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 1.29 0.51 0.77 0.96 0.00 
IQR 0.74-1.93 0.51-0.64 0.51-1.29 0.77-1.29 0.00-0.00 
(n) (291) (59) (333) (13) (79) 
Non WHO 
prequalified 
ACT 
All Median 0.96 0.90 0.64 0.90 0.00 
IQR 0.45-1.29 0.32-1.71 0.32-0.96 0.58-1.41 0.00-0.00 
(n) (1844) (149) (449) (26) (146) 
Tablet Median 0.90 0.64 0.60 0.77 0.00 
IQR 0.64-1.29 0.32-1.29 0.32-0.84 0.58-1.29 0.00-0.00 
(n) (1377) (100) (357) (23) (119) 
Oral liquid Median 1.11 2.89 1.20 1.71 0.00 
IQR 1.11-2.06 1.71-4.80 0.86-1.74 1.71-1.71 0.00-0.64 
(n) (333) (31) (71) (3) (24) 
Granule Median 0.43 0.69 0.30 - 0.51 
IQR 0.43-0.43 0.43-2.57 0.17-0.43 - 0.51-0.51 
(n) (117) (17) (18) - (3) 
AMT 
 
All Median 1.54 2.57 0.72 0.62 0.10 
IQR 0.93-2.22 0.62-6.56 0.51-1.44 0.51-1.03 0.00-2.89 
(n) (809) (135) (761) (34) (89) 
Tablet Median 0.93 0.62 0.51 0.62 0.41 
IQR 0.72-0.93 0.31-1.23 0.36-0.82 0.51-0.71 0.10-0.41 
(n) (438) (69) (494) (26) (39) 
Oral liquid Median 2.22 6.56 1.93 1.93 5.79 
IQR 1.54-2.22 5.79-6.56 1.03-2.89 1.03-2.31 1.16-5.79 
(n) (223) (25) (213) (8) (11) 
Injectable Median 6.17 6.43 2.70 - 1.70 
IQR 3.86-7.71 3.86-15.43 1.16-3.86 - 0.00-16.46 
(n) (145) (41) (54) - (38) 
nAT 
 
All Median 0.30 0.24 0.19 0.16 0.06 
IQR 0.13-0.58 0.13-0.56 0.13-0.35 0.10-0.26 0.00-0.24 
(n) (2138) (387) (5213) (357) (431) 
Tablet Median 0.19 0.19 0.13 0.12 0.00 
IQR 0.11-0.34 0.10-0.19 0.10-0.22 0.06-0.19 0.00-0.06 
(n) (1236) (190) (2698) (202) (241) 
Oral liquid Median 0.48 0.32 0.32 0.25 0.24 
IQR 0.29-0.86 0.24-0.64 0.20-0.50 0.16-0.40 0.05-0.96 
(n) (782) (121) (2303) (150) (95) 
Injectable Median 0.34 0.63 0.22 0.30 0.16 
IQR 0.12-0.60 0.56-1.20 0.08-0.34 0.15-0.39 0.00-0.72 
(n) (120) (76) (207) (5) (95) 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 The values for median 
number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and granules); however because so few wholesaler 
and retailers stocked suppositories, and so few of these product types were observed during the audit, results are not presented separately for these categories in this table, but 
are instead provided in the appendix. 3 As these are weighted medians, medians are not the average of the middle two ordered observations for instances where there are an 
even number of observations. 4 Private health facilities include both for-profit and not-for-profit facilities; Other private outlets include supermarkets, kiosks, itinerant medicine 
sellers (hawkers) and outlet types that do not fit into any of the mentioned outlet categories; Public health facilities includes community health workers. Note: 61 of 21,031 
(0.3%) purchase price observations (19 in pharmacies, 11 in private health facilities, 29 in PPMVs/drug stores, 2 in public health facilities) were set to missing due to mark-ups in 
excess of 1000% which were likely due to errors during data collection. Data collected by the ACTwatch Group during the Nigeria 2009 Outlet Survey. www.actwatch.info 
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5. Discussion 
Supply Chain Structure and Wholesaler Characteristics 
Private commercial sector antimalarial wholesalers operate at 2 distinct levels: Although we observed 
antimalarial wholesalers to operate over 4 overlapping levels, indicating a maximum of 5 supply chain steps 
from manufacturer to retailer, most either sold only to other wholesalers (36.6%) or only to retailers 
(59.5%).  Therefore, a considerable proportion of antimalarials flowing down the distribution chain likely 
pass through 3 steps from manufacturer to retail outlet (manufacturer  intermediate wholesaler  
terminal wholesaler  retailer). 
 
Many wholesalers in Nigeria are supplied directly by manufacturers:  Nigeria has a relatively well-developed 
pharmaceutical manufacturing sector that produces a wide range of antimalarial products, including ACTs.  It 
is therefore not surprising that half of wholesalers supplying retailers (or terminal wholesalers) identified a 
manufacturer as at least one of their top two sources of antimalarials, indicating that the number of steps 
between manufacturer to retailer could often be as low as 2 (manufacturer  terminal wholesaler  
retailer).  While manufacturers in Nigeria deliver orders directly to wholesalers, manufacturers have also 
adopted several different types of distribution strategies to ensure extensive geographic coverage across this 
large country, all of which employ the use of sales representatives.  One model involves the establishment of 
vertically integrated distribution infrastructure, where the manufacturer will establish subsidiary distribution 
points across the country.  This was observed in 2 instances in Nigeria.  The other more common model 
involves the use the third-party logistics companies that have a network of warehouses throughout the 
country to serve as regional or state-level distribution points for a wide range of imported and domestically 
manufactured products, including antimalarials. [8]  Among all wholesalers, 12.4% reported being supplied 
via one of these indirect channels.   
 
Large commercial markets are important centres for antimalarial wholesaling:  These types of markets are 
more important antimalarial sources for retailers than for wholesalers, as more than half (54.7%) of all 
suppliers mentioned by retailers were located in these markets, but just 12.8% of the suppliers mentioned 
by wholesalers.  Similar findings were documented in a study conducted in 3 states which found that 51.9% 
of PPMVs procured their medicines from such markets. [21] 
 
Low level of transactions between public, private and NGO sectors:  At wholesale level, no interactions were 
observed between the public and private sectors.  At retail level, one private outlet reported a public source 
distributing subsidised antimalarials (this interaction was noted in a state piloting a model where the state-
level government medical stores was wholesaling to the private sector [8]), and only two public facilities 
mentioned a private sector source as one of their two top antimalarial suppliers.  As prolonged disruptions in 
public sector distribution chains frequently occur [10], it is reasonable to assume that some public health 
facilities rely on the private sector as a supply source of medicines, including antimalarials.  Observed 
transactions with the NGO sector were also few.  Despite being an important source of first-line drugs since 
beginning the subsidy programme in 2008, SFH was mentioned by only one retailer and 5 wholesalers as one 
of their two top supply sources for antimalarials9, and there were no mentions of SFH’s civil society 
distribution partners. There are several factors that may make SFH less likely to be mentioned as a top 
supplier of antimalarials: During the subsidy programme, SFH limited the number of packages that could be 
                                                          
9
 Each of the 5 wholesalers who mentioned SFH also engaged in retailing (i.e. they reported having either a retail pharmacy or PPMV 
license, but were also identified by an outlet as a wholesale supplier of antimalarials).  This is consistent with SFH’s distribution 
model for this particular programme where subsidised Larimal and Arsuamoon were distributed either to retailers directly or via one 
of their civil society partners. 
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purchased by retailers per transaction. Furthermore, the data collection methods only allowed supplier 
information to be collected about the two top suppliers; so although SFH may be a common supplier of 
antimalarials, they may not be among the top two.  Finally, because businesses place a great deal of value on 
offering their customers a variety of product choice, it is common for businesses to procure antimalarials 
from many different suppliers. [8] As SFH only offers a few antimalarial products, top suppliers are more 
likely to be those who carry a wider range of products.  
 
Wholesaler characteristics:  Wholesalers operating at different levels of the supply chain did not differ 
greatly in terms of their number of years in operation or the number of people working in the business. 
Those supplying wholesalers were in operation for a median of 9.5 years with a median of 8.5 employees, 
while those supplying retailers were in operation for a median of 8 years with a median of 5 employees.  
However, among those wholesalers operating at higher levels of the supply chain, there was wide variation 
in the number of people working in the business (IQR 5-25 employees).  Considering that these wholesalers 
operating at higher levels of the supply chain engage in activities ranging from pharmaceutical wholesaling 
to importing, and in some cases, manufacturing, it is reasonable to expect a wide range in the size of 
enterprise.   Also, more than half (54.9%)of all wholesalers were observed to sell other products in addition 
to pharmaceuticals, but these tended to be related products, such as toiletries (25.5%) and bed nets (24.2%). 
 
Business practices within the supply chain:  The differences between wholesalers operating at higher and 
lower levels of the distribution chain in Nigeria also extend to their business practices.  For example, 
compared to those supplying other wholesalers, a greater proportion of wholesalers supplying retailers were 
observed to have retail customers (80.6% vs. 25.6%), and to sell to PPMVs and drug stores (96.1% vs. 78.1%), 
while more of those operating at higher levels of the supply chain imported antimalarials (44.2% vs. 3.9%), 
had customers in other countries (28.6% vs. 10.7%), and delivered antimalarials to their customers (59.5% 
vs. 22.3%).  This small number of terminal wholesalers delivering to their retail customers indicates that 
many retailers go to the physical wholesaler premises to make their purchases.  This is supported by our 
findings noted above about the important role that markets play as supply sources for retailers.  Retailers 
selling relatively small volumes, such as rural PPMV and kiosk operators, may prefer to go to these markets 
in order to take advantage of the convenience, wide product availability and competitive prices that these 
commercial environments engender.  Further research into the supplier choices of retailers is needed.  One 
wholesaler characteristic that did not differ considerably across supply chain levels was that most 
wholesalers (77.9%) reported providing credit for a median of 2 weeks to selected customers. 
 
Licensing and Inspection 
Few wholesalers possessed the required license to wholesale antimalarials:  It is recognised that 
pharmaceutical regulatory bodies in Nigeria lack sufficient capacity to fully implement all regulations. [8, 9, 
12]  This is reflected in our observations that only 71.2% of wholesalers were visited by an inspector in the 
past 12 months, and of the very low numbers of wholesalers adhering to licensing requirements.  For 
example, an up-to-date license from the PCN to wholesale antimalarials was observed in only 8.0% of all 
wholesalers interviewed.   
 
PPMVs regularly engage in the wholesaling of antimalarials:  This draws attention to our finding that 19.6% 
of all wholesalers reported having only a PPMV license, which highlights the role that these types of 
medicine distributors play, not only in retailing and dispensing [21], but also in wholesaling of antimalarials.   
Among these wholesaling PPMVs, we also observed that only 22.2% employed a person with a health 
qualification – despite being required to do so – and only 86.7% stored antimalarials in acceptable 
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conditions.  Other studies have shown that many PPMVs belong to associations that provide information on 
best practices in treatment, procurement and management [8, 21]; these results may indicate that at least 
some of these wholesaling PPMVs could be willing participants in any effort to legitimise their wholesaling 
activities.  
 
Wholesaler knowledge 
Despite having changed the first-line treatment policy from chloroquine to ACT in 2004 [22], only 53.6% of 
all wholesalers were able to correctly identify either AL or ASAQ as the government recommended 
treatment for uncomplicated Pf malaria.  This may be partially explained by our observation that only 62.8% 
of wholesalers employed a staff member with any kind of health qualification, and only 16.9% reported that 
their staff had participated in any kind of in-service training related to malaria treatment in the past 2 years.  
Similar proportions of wholesalers identified an ACT as the most effective treatment for malaria for either 
adults (43.5%) or children (45.7%), and significant proportions of wholesalers mentioned SP or chloroquine 
as the most effective treatments.  Compared to East Africa were resistance was already widespread, a study 
of the therapeutic efficacy of SP in 2002 found that it was still relatively high in some regions of Northern 
Nigeria. [17]  Although this and the continued familiarity of chloroquine as the former first-line drug may 
partially explain the low levels of knowledge of and preferences for ACTs, clearly more effort must go into 
raising awareness of their benefits – particularly in light of activities to improve affordability through the ACT 
subsidy programme run by SFH and the AMFm – and some of this effort could be targeted at retailers and 
wholesalers. 
 
Availability 
First-line drug availability is high among wholesalers, but AMT and nAT availability is equally high:  
Considering the high burden of malaria in Nigeria, it is not surprising that nearly all wholesalers had 
antimalarials in stock at the time of interview.  It is encouraging to note that ACTs, and in particular the first 
line drugs, were available in more than 80% of wholesalers, but perhaps less encouraging that wholesalers 
continued to stock nATs and oral AMTs at levels comparable to ACT.  High levels of nAT and AMT availability 
may be due, at least in part, to the fact that SP is used for IPTp programmes, and that injectable AMTs are 
recommended in the national treatment guidelines for cases of severe malaria; however, 80% of all AMT 
products stocked by wholesalers were in oral dosage form.  Furthermore, while it is likely that high levels of 
nAT availability among wholesalers are partly driven by domestic capacity to manufacture these products, 
this does not appear to be the case for the high availability of ACT.  For example, although there are several 
domestic manufacturers producing a number of AL and ASAQ products, only 18.7% of audited first-line drugs 
among wholesalers were manufactured in Nigeria, while 55.0% of all audited nATs were manufactured 
domestically.  In addition, none of the domestically produced first-line ACTs are WHO prequalified, making 
them ineligible for procurement for most Global Fund-supported programmes or for receipt of subsidies 
under the AMFm – both major sources of financing for malaria treatment in Nigeria.  So although there may 
be some capacity in-country to meet domestic need for first-line treatment, it is unlikely that this capacity 
will be used to its full potential.  It is also unlikely that domestic manufacturers will begin to produce WHO 
prequalified ACTs in the near future because of the large investment that would be required to raise their 
ACT production line standards to meet WHO prequalification requirements and because of the competitive 
pressure from the large number of relatively cheap imported ACTs from counties such as China and India 
that keep margins low. 
First-line drug availability is high among wholesalers, but not among retailers:   It is interesting to note that 
the second round of the Outlet Survey in Nigeria (conducted concurrently with the Supply Chain Survey in 
2009) found that nATs were available in over 90% of private outlets, and oral AMTs were available in 46% of 
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private outlets; but with respect to ACTs, availability was 37% across all private outlets, and 26% stocked a 
quality assured first-line drug. [11]  If ACTs, and particularly first-line drugs, are generally available among 
wholesalers, why are they not being stocked by more retailers?  Issues around first-line drug affordability are 
certainly key, as a number of studies looking at the impact of interventions to reduce consumer prices show. 
[23, 24]  Two programmes currently operating in Nigeria that aim to improve first-line drug affordability, the 
private sector subsidy programme run by SFH and funded by the Global Fund operating in 18 states, and the 
AMFm which applies subsidies when quality-assured ACTs leave the factory gate, will likely have a notable 
impact on retail level availability. 
RDT availability among wholesalers is very low:  RDTs were available in less than 5% of all wholesalers.  
Although the national treatment policy for children under 5 years of age recommends presumptive 
treatment, the treatment guidelines endorse parasitological confirmation for all other suspected cases of 
uncomplicated malaria.  While there is debate about the usefulness of RDTs in contexts with high 
transmission, as is the case in some parts of Nigeria, economic analyses have shown that use of RDTs can be 
cost-effective at all but the highest levels of malarial prevalence. [25, 26]  RDTs may have a particularly key 
role to play in improving diagnostic capabilities in public and private health facilities where microscopy is 
limited.  For example, the ACTwatch Outlet Survey conducted in 2009 found that only 27.5% of public 
facilities and 36.1% of private for-profit facilities had microscopy available. [11]  
 
Sales Volumes 
ACTs are being sold, but in smaller quantities than nATs:  Although the typical volumes of ACT being sold by 
wholesalers were lower than for nATs overall, the magnitude of this difference was greater among 
wholesalers operating at lower levels of the supply chain (medians for ACT: 114.8 AETDs vs. nAT: 555.5) than 
among those operating at higher levels of the supply chain (medians for ACT: 787.4 AETDs vs. nAT: 1207.3).  
These figures reflect the fact that 70.9% wholesalers operating at lower levels of the supply chain reported 
their top selling antimalarial to be either SP or chloroquine, compared to 48.7% of wholesalers operating at 
higher levels of the supply chain.  A greater proportion of wholesalers operating at higher levels of the 
supply chain also reported their top selling antimalarial to be one of the government recommended first-line 
treatments, AL or ASAQ (33.3%) compared to wholesalers at lower levels of the supply chain (14.6%).  
Chloroquine was the former first line drug prior to the adoption of ACTs in 2004, so familiarity with this 
particular nAT may be an important driver of demand. [22]  As noted above, SP still has high treatment 
efficacy rates in some parts of the country. [17]  This may be reflected in our finding that 20.3% of 
wholesalers believed SP to be the most effective treatment for adults. In these areas, continued treatment 
success using SP combined with its very affordable price may be important factors behind the observed sales 
volumes. 
 
Non WHO-prequalified ACTs are being sold in greater quantities than WHO prequalified ACTs:  At all 
wholesaler levels of distribution chain, the typical volumes of WHO prequalified ACTs being sold were many 
times smaller than the typical sales volumes for non-prequalified ACTs.  Part of this discrepancy may be due 
to the small number of WHO-prequalified products (all of which must be imported) in comparison to the 
total number of ACT products on the market that are both imported and locally produced.  In 2008, there 
were 7 WHO-prequalified ACTs compared to 37 ACTs registered for sale in Nigeria with NAFDAC, nearly a 
fifth of which were domestically produced. [27] 
 
AMTs are not being sold in large quantities:  The typical volumes of AMT being sold by wholesalers at 
different levels of the supply chain were smaller than those for ACTs and nATs, ranging from a median of 
165.8 AETDs among wholesalers supplying other wholesalers to 38.7 AETDs among wholesalers supplying 
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retailers.  While artesunate and artemether injections are included in the national guidelines for treatment 
of severe malaria, AMT sales were dominated by AMT tablets, and less so by oral liquid preparations.  This is 
of particular concern as oral AMTs have been banned in Nigeria since 2006.  When AMTs were stocked by 
wholesalers, observed sales volumes of tablets were considerable.  For example, among those wholesalers 
supplying other wholesalers that stocked AMT tablets, the median of 309.5 AETDs sold during the week 
preceding the survey was more than double the median volume sold of WHO prequalified ACTs (138.0 
AETDs). 
 
Volumes of RDTs sold are low:  Among the very few wholesalers that were observed to have them in stock, 
the median number of tests sold during the week preceding the interview was low: 40 tests (IQR 30-50). 
 
Price and Mark-ups 
Purchase prices for nAT were much lower than for ACT and AMT:  At both wholesale and retail levels of the 
distribution chain, median purchase prices for nATs were 6-10 times lower than median purchase prices for 
ACTs or AMTs.  Because percent mark-ups are fairly consistent across antimalarial drug categories, these 
differences in purchase prices persist as products flow down the supply chain and are reflected in end-user 
prices in the private sector, thus affecting end-user affordability and demand. 
 
Percent mark-ups were relatively low overall, but wholesaler mark-ups were lower than retailer mark-ups:  At 
wholesale level, the median mid percent mark-ups ranged from 18% on ACTs to 25% on nATs, and did not 
vary considerably across dosage forms. Although higher than at wholesale level, median percent mark-ups 
among retailers were still not that high, ranging between 22% for ACTs at PPMVs to 43% for nATs at private 
health facilities, and this was consistent across dosage forms.  In addition, retail mark-ups of 100% or higher 
were infrequently observed.  These relatively low percentage mark-ups and observed consistency across 
business types and dosage forms could be a reflection of intense competition in the wholesale and retail 
markets in Nigeria.  At the lower levels of the wholesale supply chain, this may also be reflected in our 
finding that many terminal wholesalers tended to be located in the large open markets in major commercial 
centres throughout the country; at higher levels of the wholesale chain, competition may be enhanced by 
the extensive geographic coverage achieved by manufacturers, importers and large wholesalers through 
various distribution strategies (as described above).  At retail level, the wide range of outlets stocking 
antimalarials, from public health facilities to informal street hawkers, and the sheer number of outlets 
stocking antimalarial contributes to a competitive environment.   
 
ASAQ purchase price lower than AL, but both are still much more expensive than SP:  Among all wholesalers, 
the median purchase price for SP (US$ 0.29, IQR 0.21-0.61) was at least 10 times lower than the median 
purchase price for AL (US$ 4.13, IQR 3.10-6.89) or ASAQ (US$ 2.91, IQR 1.94-4.65), and a similar pattern was 
observed at retail level.  However, at private health facilities, the median purchase price for ASAQ (US$ 0.26, 
IQR 0.13-0.77) was comparable to that of SP.  This was due to the high proportion of lower-priced ASAQ 
branded as Larimal observed among this outlet type, compared to the other private sector retailer types.  To 
demonstrate, although subsidised Larimal is also targeted at PPMVs and pharmacies, less than 10% of the 
Larimal observed in PPMVs was purchased at a price lower than US$ 0.25 per AETD (approximately US$ 0.06 
per paediatric dose), and even less in pharmacies and other private outlets, such as supermarkets.  This may 
also reflect our observation that out of the 150 antimalarial supplier mentions collected from retailers during 
the ACTwatch Outlet Survey, the one mention of SFH was made by a private health facility, which may 
suggest that private health facilities are more likely to be supplied by SFH than any of the other outlet types, 
and therefore, may also be more likely to stock the subsidised ASAQ products distributed by SFH.  In 
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addition, the typical price of Larimal was also lower in retail outlets located in the states participating in the 
subsidy programme run by SFH than in those retail outlets located in non-participating states; and compared 
to all other retail outlet types, the median purchase price for Larimal among private health facilities in 
participating states was particularly low (US$0.13 per AETD in private health facilities vs. US$ 2.44 in 
pharmacies vs. US$ 1.29in PPMVs), again, potentially reflecting the greater likelihood of private health 
facilities to be supplied with subsidised products from SFH.  However, more than 80% of the observed 
Larimal among private retailers located in states participating in the subsidy programme was purchased 
above the target subsidised wholesale price of 5 NGN (US$ 0.03) per paediatric dose (or approximately US$ 
0.12 per AETD).  This is because non-subsidised versions of Larimal and Arsuamoon were being sold 
concurrently in all states and were widely available in the private sector distribution chain, as reflected in our 
observation that 41% of all wholesalers stocked ASAQ products branded as either Larimal or Asuamoon. 
 
Public facilities sometimes purchased drugs from private wholesalers and sold them to patients:  Most 
antimalarial drugs used for the treatment and prevention of malaria (i.e. ACTs for uncomplicated malaria, SP 
for IPT) that are available in public facilities are procured using external aid money, and should be supplied 
to public facilities at no cost.  This is consistent with our observation that many of these types of 
antimalarials had a purchase price of US$ 0.00 in public facilities.  However, it is common for drugs in public 
facilities to be financed through revolving drug funds (meaning that patients purchase most drugs consumed 
at public facilities and the revenue raised goes toward procuring future stock).  This is also consistent with 
our observation that public facilities paid to purchase some antimalarials, particularly for those that are not 
included in the national treatment policy, such as AMTs and nATs.  This is of particular concern as this result 
indicates that some public facilities may be failing to treat some patients according to the antimalarial policy, 
and that some patients in public facilities are paying to be treated with ineffective antimalarials.  
 
RDT purchase prices were lower than ACT purchase prices:  Among the very few wholesalers who stocked 
RDTs, the median wholesale purchase price was US$ 0.70 per test (IQR 0.52-0.90).  This was several times 
lower than the median purchase price for ACT. 
 
Conclusion 
This report has presented a number of important new insights into the market for antimalarial drugs in 
Nigeria.  The distribution chain had wholesalers operating on a number of levels giving an overall pyramidal 
shape.  However, most wholesalers either supplied only other wholesalers or only retailers, and many 
wholesalers were supplied by manufacturers (as one of their top two antimalarial sources), either directly or 
through a network of regional depots owned by the manufacturer or by a logistics company.  This means 
that most antimalarials are likely to go through either 2 or 3 steps from manufacturer to retailer.  Most 
wholesalers were not observed to have an up-to-date license permitting the wholesale of antimalarials, and 
a number of those engaged in antimalarial wholesaling were only permitted to retail over-the-counter 
medicines.  Large markets are an important source of antimalarial purchasing for retailers, but regardless of 
wholesaler type and location, ACTs, and in particular the first-line drugs AL and ASAQ, were available in most 
wholesalers.  However, AMTs and nATs were also available at comparable levels, and in terms of sales 
volumes, those of nATs far exceeded sales volumes of ACTs.  At wholesale and retail levels, percent mark-ups 
on antimalarials were relatively low and consistent across antimalarial category and business type.  This may 
be due to a high degree of competition among wholesalers and retailers.  RDTs were not widely available at 
wholesale level; however, their wholesale purchase prices were low compared to ACT purchase prices.  
 51 
 
 
6. Appendices 
 
6.1. Supplemental tables for median number of suppository and granule AETDs 
sold 
 
Table 4.8.1a: Median number of AETDs sold during the week preceding the survey (all wholesalers, 
suppositories and granules only) 
ANTIMALARIAL TYPE
1
 
Formulation
2
 
WHOLESALER CATEGORIES 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
N=142
3
 N=46
 
N=103 
All ACT All Median 137.9 787.4 114.8 
IQR 12.8-794.0 117.4-4633.1 8.4-530.8 
Suppository Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Granule Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Non-WHO 
prequalified ACT 
All Median 94.0 418.0 70.2 
IQR 2.6-556.4 4.9-2266.7 2.6-374.0 
Suppository Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Granule Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
AMT All Median 42.0 165.8 38.7 
IQR 3.8-272.1 0.0-934.9 11.0-206.4 
Suppository Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Granule Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
nAT All Median 562.9 1207.3 555.5 
IQR 163.6-2006.6 0.0-8144.7 166.7-1635.3 
Suppository Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
Granule Median 0.0 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 0.0-0.0 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria; 2 The values for median number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, 
oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of 
these product types were observed during the audit, results for these dosage forms are instead provided in the appendix. 3 For 
antimalarials: there were a total of 136 wholesalers with antimalarial sales volumes (reported or imputed or set as null if did not stock). 
Note on imputation process for antimalarial sales volumes: during the study, 205 wholesalers were identified, of which 137 were 
interviewed successfully.  Of the remaining, 3 were partially interviewed, 27 refused, 33 were not screened because a respondent was not 
available, the business had closed or could not be found, and 5 did not stock antimalarials at the time of the survey (Table 1). These 68 
wholesalers were excluded from the volumes analysis. Two additional wholesalers did not stock antimalarials at the time of interview but 
did so in the three months prior to interview, so their sales volumes were set as 0 for all antimalarial categories .   Overall, there were a 
total of 2531 antimalarials audited, and 903 (35.7%) had missing sales volumes that were imputed using the mi impute pmm command.   
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Table 4.8.2a: Median number of AETDs sold during the week preceding the survey (among 
wholesalers stocking corresponding antimalarial drug category/RDT at the time of the survey, 
suppositories and granules only) 
ANTIMALARIAL TYPE
1
 
Formulation 
WHOLESALER CATEGORIES
3
 
ALL 
WHOLESALERS  
SUPPLY 
WHOLESALERS  
SUPPLY 
RETAILERS 
All ACT All Median 200.0 853.2 140.9 
IQR 49.8-890.3 162.5-6807.9 35.1-715.5 
(n) (118) (36) (89) 
Suppository Median 20.3 - 20.3 
IQR 0.9-57.9 - 0.9-57.9 
(n) (4) - (4) 
Granule Median 3.1 15.4 2.1 
IQR 0.8-26.9 2.0-43.1 0.8-13.3 
(n) (27) (8) (21) 
Non-WHO 
prequalified 
ACT 
All Median 193.5 809.7 136.9 
IQR 45.4-760.4 200.0-4426.3 30.6-557.9 
(n) (103) (30) (79) 
Suppository Median 20.3 - 20.3 
IQR 0.9-57.9 - 0.9-57.9 
(n) (4) - (4) 
Granule Median 3.1 15.4 2.1 
IQR 0.8-26.9 2.0-43.1 0.8-13.3 
(n) (27) (8) (21) 
AMT All Median 90.8 667.6 61.6 
IQR 31.5-333.8 257.1-3424.3 25.0-265.4 
(n) (107) (23) (88) 
Suppository Median 32.3 - 32.3 
IQR 8.0-56.7 - 8.0-56.7 
(n) (2) - (2) 
Granule Median - - - 
IQR - - - 
(n) - - - 
nAT All Median 840.0 2207.9 563.3 
IQR 261.7-2149.3 1049.9-14032.1 218.7-1777.3 
(n) (121) (29) (97) 
Suppository Median 58.7 117.9 80.0 
IQR 36.5-140.0 35.7-200.0 37.4-200.0 
(n) (4) (2) (3) 
Granule Median - - - 
IQR - - - 
(n) - - - 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test 
for malaria.  2 The values for median number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, 
oral liquids, injectables and granules); however because so few wholesaler and retailers stocked suppositories or granules, and so few of 
these product types were observed during the audit, results for these dosage forms are instead provided in the appendix. 3 (n) is the 
number of wholesalers at a given level who stocked antimalarials for corresponding drug category. 
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6.2. Range of health and non‐health retail outlets selling medicines in Nigeria 
Public Health Facilities N Description 
University teaching hospital / 
Federal Medical Centre 
29 
These tertiary level public health facilities are designated as 
referral hospitals for the State. They have specialized clinics 
with qualified personnel. 
 
Federal Medical Centres (FMCs) are headed by a Chief Medical 
Director appointed by Federal Government, funded by and 
reporting to the Federal Government. They conduct 
postgraduate training of health providers including doctors and 
nurses. Unlike university teaching hospitals, FMCs are not 
attached to any specific university or medical school. 
 
By definition, university teaching hospitals are linked to a 
university or medical school. They are headed by a Chief 
Medical Director, and regulated by the Medical and Dental 
Council. Some teaching hospitals are privately owned and the 
distinction between government-owned and private-owned 
facilities has made during the survey. 
General / Specialist hospital 24 
These secondary public health facilities are funded by and 
report to State governments. 
 
General hospitals typically serve urban or peri-urban areas with 
a catchment area covering 200,000 to 300,000 people. They are 
headed by a Medical Superintendant, and have facilities for 
diagnosis, in-patient admission, and surgery. They include 
pharmacy section(s), dispensary unit(s), an ambulance, and a 
few residential houses for staff on emergency duties. General 
hospitals may host internships for doctors under supervision, 
but do not perform postgraduate training.  
Primary Health Care Centre 
(PHCC) 
202 
These primary health facilities are managed and operated at 
the local government area level. 
 
They are the smallest of all government-owned health facilities 
and offer fewer services than those found at tertiary and 
secondary level facilities. Health centres are located in both 
urban and rural settings, and have a typical catchment area 
covering 10,000 to 30,000 people. 
 
They are usually manned by one or two nurses with some 
community health extension workers and a few auxiliary staff. 
However, some are operated by doctors, while others have 
doctors that periodically visit to make major decisions or run 
specialist clinics. Services provided include community IMCI; 
family planning; focuses ANC; routine immunization; and 
PMTCT. 
Private, not-for-profit facilities N Description 
Non-Governmental Organization 
(NGO) Hospital / Health Centre 
11 
These health facilities operate at different levels of the health 
system, depending on their size. They are funded and supported 
by non-governmental organizations and provide medical 
consultations, diagnoses, and prescription medicines at a 
nominal cost. 
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Community health workers N Description 
Community Health Extension Worker 19 
This cadre of trained health worker is found mostly at the 
primary health care level and provides services directly to the 
communities in which they work. While most of them are 
attached to government facilities, some of them operate at 
privately owned outlets, such as PPMVs, or from their residential 
homes. 
Pharmacy N Description 
Pharmacy 409 
These outlets are registered by the Pharmacy Council of Nigeria 
and are authorized to sell all classes of medicines, including 
prescription medicines. They usually employ nurses and intern 
pharmacists. 
 
Pharmacies are highly regulated by the National Agency for Food 
and Drug Administration and Control (NAFDAC). They are 
privately owned, either by registered pharmacists or individuals 
who employ the services of a registered pharmacist. In Nigeria, 
pharmacies are overwhelmingly located in urban areas in 
commercial zones. 
Drug Store N Description 
Propriety patent medicine vendors / 
Drug Store 
1,031 
These are small to medium sized outlets, equivalent to drug 
shops in other ACTwatch countries. PPMVs may be registered by 
the Directorate of Pharmaceutical Services (DPS), but the 
majority of them are not registered. 
 
They are legally allowed to sell over the counter (OTC) 
medicines, however a number of them also illegally stock 
prescription medicines. (In 2006, NAFDAC de-classified ACTs 
from prescription-only to OTC; hence ACTs are legally available 
at PPMVs.) Some operate without a license, especially at the 
village level or remote areas. 
 
PPMVs are ubiquitous across Nigeria and, given the lack of 
pharmacies in rural settings, serve as accessible medicine outlets 
for consumers. Staff typically have little or no training in health 
service delivery, although a small proportion of PPMVs are 
owned by nurses or other health workers, such as community 
health extension workers. 
Private-for-profit N Description 
Private hospitals / clinics 405 
These are non-governmental health facilities. Just as with public 
health facilities, private hospitals and clinics are classified in 
terms of their capacity— tertiary, secondary, or primary. For 
this study, all three levels have been grouped into one category. 
Hence, they can range from offering comprehensive health 
services to being limited in scope. Likewise, staff range in 
qualification and number. There is usually a dispensing section, 
but in some cases, the doctors may dispense medications 
themselves. 
Retail stores N Description 
Supermarket / Minimarket / 
Provision store 
3,305 
Small businesses which sell household products, food, and 
beverages. These stores may also sell medicines, usually 
antipyretics. They are unlicensed. 
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6.3. Calculating AETDs:  antimalarial treatment and equivalent adult treatment dose 
Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Amodiaquine 1800mg   WHO Use of Antimalarials, 2001 
Amodiaquine-Sulfadoxine-
Pyrimethamine 
1800mg Amodiaquine  WHO Model Formulary, 2008 
Arteether 1050mg   WHO Use of Antimalarials, 2001 
Artemether 960mg   WHO Use of Antimalarials, 2001 
Artemether-Lumefantrine 480mg Artemether  WHO Model Formulary, 2008 
Artemisinin-Naphthoquine 2400mg Artemisinin Manufacturer Guidelines for this product 
are 1000mg Artemisinin in a single dose. 
Such a short ACT regimen is highly suspect. 
This treatment dose is based upon the WHO 
Artemisinin-MQ recommendation of a total 
dose of 40mg/kg. 
WHO Use of Antimalarials, 2001 
Artemisinin-Piperaquine 576mg Artemisinin Treatment dose based on Artemisinin-
Piperaquine-Primaquine value, below. 
As below 
Artemisinin-Piperaquine-
Primaquine 
576mg Artemisinin  Tangpukdee, N. et al. 2008. Efficacy of 
Artequick versus artesunate-mefloquine in 
the treatment of acute uncomplicated 
falciparum malaria in Thailand. The 
Southeast Asian Journal of Tropical 
Medicine and Public Health. 39(1): 1-8 
http://imsear.hellis.org/handle/12345678
9/33676  
Artesunate 960mg   WHO Use of Antimalarials, 2001 
Artesunate-Amodiaquine 600mg Artesunate  Manufacturer Guidelines 
(Winthrop/Coarsucam – Sanofi Aventis) 
Artesunate-Halofantrine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
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Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Artesunate-Lumefantrine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
Artesunate-Mefloquine 600mg Artesunate  Manufacturer Guidelines 
(Artequin Adult – Mepha) 
Artesunate-Piperaquine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
Artesunate-Pyronaridine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
Artesunate-Sulfadoxine-
Pyrimethamine 
600mg Artesunate  Manufacturer Guidelines 
(Co-arinate – Dafra) 
Atovaquone-Proguanil 3000mg Atovaquone  Manufacturer Guidelines 
(Malanil – GSK) 
Chloroquine 1500mg   WHO Model Formulary, 2008 
Chloroquine-Sulfadoxine-
Pyrimethamine 
1500mg Chloroquine  WHO Model Formulary, 2008 
Chlorproguanil-Dapsone 360mg Chlorproguanil  Manufacturer Guidelines 
(LapDap – GSK) 
Dihydroartemisinin 480mg   Manufacturer Guidelines 
(Cotecxin – Holleypharm; MALUether – 
Euromedi) 
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Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Dihydroartemisinin-
Amodiaquine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Halofantrine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Lumefantrine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Piperaquine 
360mg Dihydroartemisinin  Manufacturer Guidelines 
(Duo-cotecxin – Holleypharm) 
Dihydroartemisinin-
Piperaquine-Trimethoprim 
256mg Dihydroartemisinin  Manufacturer Guidelines 
(Artecxin – Medicare Pharma; Artecom – 
Ctonghe) 
Dihydroartemisinin-
Pyronaridine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Sulfadoxine-Pyrimethamine 
360mg Dihydroartemisinin  Manufacturer Guidelines 
(Dalasin – Adams Pharma) 
Dihydroartemisinin-
Mefloquine 
360mg Dihydroartemisinin  Manufacturer Guidelines 
(Meflodisin – Adams Pharma) 
Halofantrine 1500mg  This dose is for halofantrine hydrochloride 
as the strength is normally reported in this 
manner. The total dose for halofantrine 
base is 1398 mg. 
Manufacturer Guidelines 
(Halfan – GSK) 
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Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Hydroxychloroquine 2000mg   Manufacturer Guidelines 
(Plaquenil – Sanofi Aventis) 
Mefloquine 1000mg   WHO Use of Antimalarials, 2001 
Mefloquine-Sulfadoxine-
Pyrimethamine 
1000mg Mefloquine  WHO Use of Antimalarials, 2001 
Primaquine 45mg  This dose is for the gametocytocidal 
treatment of P. falciparum. 
WHO Model Formulary, 2008 
Quinacrine 2212mg  Recommendations for malaria treatment 
are very dated. This value is the treatment 
regimen for giardiasis, which has also been 
used in the treatment for malaria.  
Gardner, T. B. and Hill, D. R. 2001. 
Treatment of Giardiasis. Clinical 
Microbiology Reviews. 14(1): 114-128 
http://cmr.asm.org/cgi/content/full/14/1/
114#T2  
Quinimax 10500mg   Manufacturer Guidelines 
(Quinimax – Sanofi Aventis) 
Quinine 12600mg  This dose is for quinine sulphate, a salt, as 
quinine strengths are normally reported for 
salts. 
The total dose for quinine base based on 
24mg/kg is 10080mg for a 60kg adult. 
WHO Model Formulary, 2008 
Quinine-Sulfadoxine-
Pyrimethamine 
12600mg Quinine This dose is for quinine sulphate, a salt, as 
quinine strengths are normally reported for 
salts. 
The total dose for quinine base based on 
24mg/kg is 10080mg for a 60kg adult. 
WHO Model Formulary, 2008 
Sulfadoxine-Pyrimethamine 1500mg Sulfadoxine  WHO Model Formulary, 2008 
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6.4. Rationale & method to calculate weights and how to use weights to calculate 
indicators 
 
Study design 
Stratification was done according to the country’s six geo-political zones: North Central, North West, North 
East, South West, South East and South-South. The primary sampling unit is the ‘locality’, also known as a 
village or town depending on urbanization and size. A one-stage probability proportional to size (PPS) 
technique was used in sample selection, with the locality population as the measure of size and 19 localities 
per stratum.  Notably, the population sizes of localities have a big variation – from small rural villages with 
populations in the low hundreds to large urban state capitals in excess of 300, 000. The generic ACT Watch 
outlet survey study design describes the selection of a primary sampling unit as an administrative division 
that hosts a population of approximately 10,000-15,000 inhabitants; however, in Nigeria there are no 
administrative divisions with populations consistently within this range. The following approach was agreed 
upon and used in the survey: 
i. A census of all PHF (Public Health Facility)  and POPs (Part One Pharmacy) was conducted in 20 
selected locations for each stratum 
ii.  A census of all private health facilities, registered pharmacies was conducted in 19 selected localities 
in each stratum, regardless of the population size 
iii. A census of Proprietary Patent Medicine Vendor (PPMVs) and informal sector(such as supermarkets, 
hawkers, CHWs, shops) was conducted ONLY in three selected EAs for  ‘large areas’ (>50,000 
inhabitants) among the 19 selected localities 
iv. A full census of PPMVs and informal sector was conducted in ‘medium to small’ geographical areas 
among the 19 selected localities  
A booster sample comprised of an additional locality in each of the six geo-political zones selected on the 
basis of having large population size. A census of all PHFs and registered pharmacies in the booster sample 
was conducted. 
 
Weighting approach 
Weights were calculated differently for the different outlet categories and specific to analysis type but 
generally involved the inverse of the selection probability and corresponding population size. We used the 
locality populations for all PHFs, private health facilities, and registered pharmacies and for all analysis 
involving both booster and non-booster samples (including volumes analysis) and EAs populations for PPMVs 
and informal outlets in ‘large areas’. There was no adjustment to the weights with the assumption that a full 
census of PHF and registered pharmacies was done in all localities. We did not have an updated list of these 
facilities to verify the coverage of the enumeration. 
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The sampling weight for the corresponding units given in above was calculated by: 
 
i. For the PHFs (Public Health Facility) and POPs (Part One Pharmacy) 
 
populationlocality (20) stratum in localities ofnumber 
population stratum

iWeight
 
 
ii. For all the private health facilities and registered pharmacies other than PHFs  & POP 
 
populationlocality (19) stratum in localities ofnumber 
population stratum

iWeight
 
 
iii. For PPMVs and informal outlets in  a ‘large areas’ (>50,000 inhabitants) 
 
population  EA (19) stratum in localities ofnumber 
population stratum

iWeight
 
 
iv. For  PPMVs and informal outlets in a ‘medium to small’ geographical areas  
 
populationlocality (19) stratum in localities ofnumber 
population stratum

iWeight  
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